|
MINISTRY OF HEALTH
-------
|
SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness
---------------
|
|
No. 20/2022/TT-BYT
|
Hanoi, December 31, 2022
|
CIRCULAR
INTRODUCING NOMENCLATURES AND PAYMENT RATES, CONDITIONS OF CHEMICAL MEDICATIONS, BIOLOGICALS, RADIOPHARMACEUTICALS AND TRACERS UNDER HEALTH INSURANCE POLICYHOLDERS’ RECEIVED COVERAGE
Pursuant to the Law on Health Insurance No. 25/2008/QH12 dated November 14, 2008 that is amended and supplemented by the Law No. 46/2014/QH13 dated June 13, 2014;
Pursuant to the Government's Decree No. 146/2018/ND-CP dated October 17, 2018, elaborating and providing guidance on the implementation of a number of articles of the Law on Health Insurance;
Pursuant to the Government's Decree No. 95/2022/ND-CP dated June 15, 2022, defining the functions, tasks, powers and organizational structure of the Ministry of Health;
Upon the request of the Director of the Department of Health Insurance under the Ministry of Health,
The Minister of Health herein promulgates the Circular to introduce nomenclatures and payment rates, conditions of chemical medications, biologicals, radiopharmaceuticals and tracers under health insurance policyholders’ received coverage.
Article 1. Nomenclatures enclosed in this Circular
1. Nomenclature of chemical medications and biologicals under health insurance policyholders’ received coverage is given in Appendix I hereto (hereinafter referred to as Appendix I).
2. Nomenclature of radiopharmaceuticals and tracers under health insurance policyholders’ received coverage is given in Appendix II hereto (hereinafter referred to as Appendix II).
Article 2. Structure of Nomenclatures of medications and grading of hospitals providing medications
1. The Nomenclature of chemical medications and biologicals, which are arranged into groups by their medical effects, (Appendix I) is divided into 08 columns as follows:
a) 1st column: Number of items included in the Nomenclature;
b) 2nd column: Name of medications. The International Non-proprietary Name (INN) of active pharmaceutical ingredient is used. If INN of a medication is not available, the name of active ingredient obtaining the market authorization or the name specified in the MoH's guidance on diagnosis and treatment may be used instead. All items are arranged according to large groups and ATC (Anatomy, Treatment, Chemistry) codes;
c) 3rd column: Route of administration, form of administration (method of delivery) of each medication; medication content not specified; dosage forms not specified, except those showing clear difference in medical efficacy or effect. Route of administration or form of administration (method of delivery) of medications included in the Nomenclature of chemical medications and biologicals is understood and accepted as follows:
- Oral administration, including those that are swallowed, chewed or dissolved in mouth;
- Injection administration, including those administered by intramuscular, subcutaneous, intradermal, intravenous, infusion, intravenous, intra-articular, intraocular, intravitreal or intraperitoneal injection;
- Topical administration, including those applied, rubbed, stuck, or sprayed onto the skin; wiping or applied to the mucous membranes;
- Insertion administration, including those inserted into the vagina, anus, enema, rectum, and under the tongue;
- Respiratory administration, including nebulizers, inhalers (formulation of solution, suspension, powder for inhalation), aerosols;
- Ophthalmic administration, those given into the eye by drops, gel or ointment; otic administration, including those given by drops into the ear; nasal administration, including those given into the nose by spray or pump;
- Other routes of administration or forms of administration specified in the Nomenclature, including several medications used in special ways;
d) 4th, 5th, 6th and 7th column: Grade of the hospital that is authorized to provide listed medications and get paid by the health insurance fund. Below are medications or active ingredients in the Nomenclature (Appendix I) corresponding to the grades of medical establishments that get paid by the health insurance fund:
- 4th column indicates the special-grade and grade-I hospitals providing the covered medications;
- 5th column indicates the grade -II hospitals providing the covered medications;
- 6th column indicates the grade-III and grade-IV hospitals, including general clinics affiliated to general hospitals or medical centers of districts, towns or provincial cities and central cities, general clinics, specialized clinics, or private midwifery facilities that have been professionally classified by competent state agencies as equivalent to grade-III hospitals providing the covered medications;
- 7th column indicates polyclinics, specialized clinics, private midwifery facilities that have not been professionally classified yet; commune, ward, township health stations, agency health stations, and equivalents (hereinafter collectively referred to as commune health stations) providing the covered medications;
dd) 8th column: Coverage conditions, rates and notes on several medications.
2. The Nomenclature of radiopharmaceuticals and tracers (Appendix II) is divided into 05 (five) columns as follows:
a) 1st column: Number of items included in the Nomenclature;
b) 2nd column: Name of medications. The International Non-proprietary Name (INN) of medications is used. Where INN is not available, the name of active ingredient obtaining marketing authorization is used;
c) 3rd column: Route of administration;
d) 4th column: Dosage form;
dd) 5th column: Unit of administration.
Radiopharmaceuticals and tracers in the Nomenclature (Appendix II) are not classified according to hospital grades and may only be used at medical establishments permitted by competent authorities to perform medical diagnosis and treatment by application of radiopharmaceuticals and tracers.
Article 3. General principles of coverage of medical costs incurred by patients holding health insurance policies
1. The health insurance fund shall cover costs of the covered medications incurred by patients according to the actual quantity of medications used, except those specified in clause 5 of Article 5 of this Article; the actual procurement prices of these medications defined in law on bidding and the range of health insurance coverage and amounts under law on health insurance.
2. The health insurance fund shall pay for a medication when the prescription for such medication is conformable to the prescription stated in one of the following documents:
a) The leaflet attached to the dossier of registration of the medication licensed by the Ministry of Health;
b) The leaflet attached to the dossier of registration of the proprietary medicine or reference biological licensed by the Ministry of Health;
c) The guidelines for diagnosis and treatment adopted by the Ministry of Health;
d) The most updated version of the National Pharmacopoeia of Vietnam.
3. The health insurance fund shall not pay for a medication if:
a) The decision on suspension or recall of the medication or the batch comprising that medication is adopted. Any medication or batch receiving the suspension or recall decision as stated above shall not be covered according to the scope of application of that decision specified in the written notification of or the decision on suspension of marketing authorization or recall of that medication or batch issued by the Ministry of Health;
b) The cost of that medication has been included in the price of technical, medical examination and medical bed service or the lump-sum price per a patient case in accordance with regulations in force;
c) The portion of the cost of that medication is paid by the state budget or other sources of fund;
d) That medication is used in clinical tests or scientific researches.
Article 4. Regulations on payment of reimbursement to several medical establishments
The health insurance fund shall pay costs of medications to a number of medical establishments that comply with Article 3 and 5 of this Circular, and certain regulations in a number of situations as follows:
1. For any public medical establishment signing a contract to provide medical services covered by health insurance, but not graded yet: Based on its human resources, medical equipment, facilities and the list of technical services approved by the competent authority, the Department of Health shall preside over, and cooperate with the provincial Social Insurance in, determining in writing the use of medications by that medical establishment according to its corresponding hospital grade.
2. For any public medical establishment under a People’s armed force that signs a contract to provide the medical services covered by the health insurance fund, but not graded yet: Based on its human resources, medical equipment, facilities and the list of technical services approved by the competent authority, the body directly managing that medical establishment shall preside over, and cooperate with the provincial Department of Health and the social insurance agency which enters into the contract to provide the medical services covered by the health insurance fund in, determining in writing the nomenclature of covered medications provided by that medical establishment according to its corresponding hospital grade.
3. Where any medical establishment renders the technical service approved by the competent authority, it may use covered medications to carry out that technical service (including the covered medications to be provided by any higher-grade hospital). That medical establishment shall compile the list of those medications and submit it to the social insurance agency entering into the contract to provide medical services covered by health insurance with it for use as a proof of payment.
4. With regard to any provincial specialized medical establishment providing medications, not including technical services, based on its human resources, medical equipment, facilities and patient’s needs, and medical treatment and diagnosis and treatment guidelines of the Ministry of Health, the Department of Health shall preside over, and cooperate with the provincial Social Insurance in, determining in writing the list of medications to be provided by a higher-grade medical establishment that it can provide and get paid by the health insurance fund (including those susceptible to conditions regarding grades and specialties of medical establishments in the 8th column of the Nomenclature of medications specified in Appendix I), on condition that the grade of such higher-grade medical establishment is not higher than the grade of the highest-grade provincial general hospital located in the local area in question.
Article 5. Regulations on payment of reimbursement for covered costs of several medications
The health insurance fund shall cover costs of medications incurred by patients holding health insurance policies when such coverage conforms to Article 3 and 4 of this Circular, and certain regulations in the situations as specified below:
1. Costs of other chemical isomers or other salt forms of active ingredients (even including single components and multi-component combinations, except vitamins and minerals) included in the Nomenclature of medications (Appendix I) shall be covered if they have the same indications as chemical forms or drugs listed in that Nomenclature.
2. With respect to a medication classified into a group of medications that is used for curing the disease cured by another group of medications, such medication shall be covered if the prescription for such medication is conformable to that specified in clause 2 of Article 3 herein.
3. Several medications that patients use are susceptible to regulations on insurance coverage conditions and rates as defined in 8th column of the Nomenclature of medications (Appendix I).
4. If a patient who is prescribed a medication administers only a portion of the smallest packing unit of such medication (i.e. pediatric medications, oncological medications), and the remaining portion is left unused (i.e. no patient is given the same prescription; the remaining portion does not reach the recommended dose; or its shelf life expires), the health insurance fund shall fully cover the costs incurred at the price of that portion of the smallest packing unit.
5. If some medications in liquid or compressed form (such as pharmaceutical oxygen, nitric oxide) are not packaged separately for use by each individual patient, the health insurance fund shall pay for the amount of medication used according to the actual length of time of breathing of such oxygen per patient multiplied (x) the amount of oxygen breathed per a unit of time (minute or hour).
6. For tracers and radiopharmaceuticals:
a) For tracers: Based on technical services and the number of patients who are directly offered such technical services, the medical establishment providing such services shall calculate the average number of kits or vials used rendering the corresponding technical service. The health insurance fund shall cover costs of the tracer used at the predetermined price multiplied (x) the actual quota of the tracer on average;
b) For radiopharmaceuticals: Based on the rate of radioactive decay, the supply of radiopharmaceuticals, the cycle of import of radiopharmaceuticals and the actual number of patients using radiopharmaceuticals, the medical establishment shall determine the actual rate of radiopharmaceuticals used on average. The health insurance fund shall cover costs of the radiopharmaceutical used at the predetermined price multiplied (x) the actual rate of the pharmaceutical used on average;
c) The statistics and calculation of costs of technical services rendered by using radiopharmaceutical and tracers shall be as defined in Appendix III to this Circular.
7. Medications marked with an asterisk (*) are drugs that may be used after medical consultation, except in case of emergencies. For antibiotics marked with an asterisk (*), the health insurance fund shall pay when the pre-prescription consultation process is carried out as defined in the Instructions of management of antibiotic uses in hospitals given by the Ministry of Health.
8. For cancer drugs and immunosuppressives:
a) They must be used to treat cancer according to prescriptions by doctors who are licensed to practice medical examination and treatment, and have their scope of practice including oncology or nuclear medicine or blood transfusion hematology, and used at medical establishments providing cancer treatment services, except for the case specified at point b of this clause, including:
- Oncology, hematology, blood transfusion, nuclear medicine facilities;
- Oncology, hematology, blood transfusion and nuclear medicine departments or centers of institutes, specialized hospitals or general hospitals;
- Various types of organization tasked with cancer treatment that are specified their operational regulations or the charters approved or recognized by competent authorities.
b) For medications used for treatment of the diseases other than cancer: The health insurance fund shall pay upon receipt of the guidance on diagnosis and treatment from the Ministry of Health or a medical establishment. Where such guidance is not available, the medical consultation with oncology doctors shall be required. If both such guidance and oncology doctors are not available, the medical consultation under the control of the medical establishment shall be needed before the prescription is used.
9. For medications prepared or formulated (including pharmaceutical oxygen and nitric oxide) at a medical establishment:
a) The health insurance fund shall pay when:
- These medications contain ingredients specified in the Nomenclature of medications enclosed herewith. If such medication is made from various active ingredients, each active ingredient of such finished medication must be included in the Nomenclature of medications appended to this Circular in the form of an element or a compound. If such medication is made from various active ingredients, any of which is not included in the Nomenclature of medications appended to this Circular, the instructions given in point d of this clause shall be followed;
- The routes of administration, dosage forms of, or grades of hospitals permitted to provide, these medications must be conformable to those defined in the Nomenclature of medications appended hereto;
- These medications are only used at that medical establishment.
b) Based on the needs for use of a medication, a medical establishment shall take the following actions:
- If that medical establishment is directly under the Ministry of Health, its head shall be responsible for developing the procedures for preparation or formulation of such medication, quality standards, prices or costs of that medication; seeking an agreement with a social insurance agency on the price or cost of the medication in question as a basis for the health insurance fund's coverage or reimbursement;
- For a medical establishment under a People’s armed force; Instructions given by the Ministry of Public Security and/or the Ministry of National Defense shall be followed;
- For a medical establishment directly under a Department of Health, and a private medical establishment, regulations regarding prices shall be obeyed.
c) The price and cost of such medication shall be developed according to:
- Costs of each active ingredient of such medication which are based on the price at which the medical establishment purchases that medication.
- Wastage costs (if any);
- Excipient and auxiliary material costs;
- Disinfection and sterilization costs (if any);
- Preparation or formulation costs, including electricity, water, and fuels;
- Costs of packaging or consumables;
- Costs of materials, supplies, chemicals and auxiliary materials for quality inspection before testing;
- Testing costs;
- Participating personnel costs;
- Administrative costs and depreciation costs of machinery: The health insurance fund shall pay the administrative and depreciation costs of machinery according to the roadmap for adjusting the elements constituting the prices of the covered medical services at the same time same-grade hospitals nationwide apply the prices of the covered medical services adopted by the Minister of Health;
d) d) If a medication which is prepared or formulated is made from various active ingredients, any of which is not included in the Nomenclature of medications appended to this Circular, the health insurance fund shall pay in accordance with point a, b and c of this clause, except costs of the active ingredient that is not specified in the Nomenclature of medications appended hereto;
dd) The health insurance fund shall not pay for prepared or formulated medications when there are commercial drugs available on the market that have the same ingredients, content and dosage forms as the prepared or formulated medications, and when the prices of the prepared or formulated medications are lower than the prices or costs thereof at a medical establishment.
10. For medications used in remote consultations
a) The health insurance fund shall pay coverage to the patients who are given emergency care at medical establishments and administer medications according to medical guidance or prescription offered in remote consultations with other medical establishments;
b) The health insurance fund shall pay without depending on the hospital's grade as defined in this Circular (including medications susceptible to regulations on conditions relating to grades and specialties of medical establishments at 8th column of the Nomenclature of medications (Appendix I)) when the following requirements are satisfied:
- A medical consultation is carried out according to the task of command over the medical establishment network, or the technology transfer contract;
- Medications provided by medical establishments for patients are purchased as per law on bidding;
- The medical consultation report is prepared by using the report form given in Appendix I to the Minister of Health's Circular No. 49/2017/TT-BYT dated December 28, 2017, prescribing remote medical activities.
11. If a patient cannot go to the medical establishment due to a group-A infectious disease that breaks out, the health insurance fund shall pay as follows:
a) If the patient cannot come to a medical establishment that has issued the appointment form to him/her to receive medical services and medications, the medical establishment or the patient may choose one or more of the following ways:
- The medical establishment issuing the appointment for medical examination delivers medications the other medication establishment where the patient can come to continue the medical treatment and provide medications for him/her. The health insurance fund shall repay the cost of a medication used for treating a patient to the medical establishment receiving that medication at the purchase price quoted by the medical establishment transferring it according to the extent of health insurance benefits and the rate of health insurance benefits enjoyed;
- The patient may authorize his/her representative to act on his/her behalf to receive a medication at the medical establishment issuing the appointment form for re-visit or at another medical establishment receiving the medication from the former.
Such authorization must be granted in writing, which must clearly provide information about the patient's name, date of birth, identity card number or citizen identification number or passport number of the patient and the person authorized to receive the medication. When receiving drugs, the person authorized to receive the medication must present documents showing information consistent with the information given in the authorization document.
Medical establishments shall be responsible for ensuring the information written in the authorization document is consistent with the information shown in the papers presented by the authorized person to receive medications at medical establishments;
- For patients suffering from tuberculosis, latent TB, drug-resistant tuberculosis or patients suffering from HIV/AIDS, and medications used to treat non-communicable diseases, the medical establishment issuing the appointment form for re-visit shall appoint a person or hire a third-party carrier to transport the medication to the patient for continued treatment and drug use.
b) With regard to a patient who is being treated as an inpatient prescribed for referral, if he/she cannot be referred due to the epidemic situation, the health insurance fund shall pay the costs of medications used for his/her treatment which are purchased by the medical establishment in accordance with law on bidding, regardless of the hospital's grade prescribed in this Circular, including the medications susceptible to conditions on grades and specialties of medical establishments specified in the 8th column of the Nomenclature of medications (Appendix I).
Article 6. Implementation
1. The Department of Health Insurance – the Ministry of Health shall be responsible for directing, guiding, disseminating, examining, evaluating, preliminarily and finally reviewing the implementation of this Circular nationwide.
2. The Social Insurance of Vietnam shall assume the following responsibilities:
a) Direct, guide and inspect the implementation of this Circular by social insurance agencies in provinces and centrally-affiliated cities;
b) Direct social insurance agencies of provinces and centrally-affiliated cities to reach agreement with medical establishments on the prices or costs of medications prepared or formulated at medical establishments as a basis for payment of covered medical costs.
3. Departments of Health of provinces and centrally-affiliated cities shall be responsible for directing, guiding, disseminating, examining, evaluating, preliminarily and finally reviewing the implementation of this Circular under their authority.
4. Medical establishments shall assume the following responsibilities:
a) Develop Nomenclatures of chemical medications, biologicals, radiopharmaceuticals and tracers used there, including medications prepared or formulated by themselves (if any), and send them to social insurance agencies signing contracts for provision of medical services covered by the health insurance fund, enclosing contractor selection plans, contractor selection results and preparation or formulation procedures, quality standards, prices or costs of medications prepared or formulated by themselves as a basis for payment of medical costs and expenses covered by the health insurance fund;
b) Where there is any change or addition to the Nomenclatures of medications that they provide, they shall send the updated Nomenclatures to the social insurance agencies signing contracts for provision of covered medical services as a basis for payment of health insurance benefits;
c) Where any medical establishment is not capable of continuing to provide technical services and approved medications, they shall have to report to competent authorities and social insurance agencies signing contracts for provision of medical services covered by the health insurance fund to seek their approval of suspension of these technical services, use of these medications and health insurance coverage.
Article 7. Entry in force
1. This Circular is entering into force as of March 1, 2023.
2. The Circular No. 30/2018/TT-BYT dated October 30, 2018 of the Minister of Health, introducing Nomenclatures, rates, conditions of payment of costs of chemical medications, biologicals, radiopharmaceuticals and tracers under health insurance policyholders’ received coverage; the Circular No. 01/2020/TT-BYT dated January 16, 2020 of the Minister of Health, amending and supplementing the Circular No. 30/2018/TT-BYT; the Circular No. 20/2020/TT-BYT dated November 26, 2020 of the Minister of Health, amending and supplementing the Circular No. 30/2018/TT-BYT shall be invalidated as from the entry into force of this Circular.
Article 8. Grandfather clause
1. Where patients holding health insurance cards are hospitalized as inpatients before the effective date of this Circular and have to continue to receive such inpatient treatment at medical establishments after the effective date of this Circular, the regulations laid down herein shall be applied to the entire period of their inpatient treatment.
2. For cancer patients who used doxorubicin administered by injection in liposome dosage form; erlotinib administered orally; gefitinib administered orally; sorafenib administered orally (for treatment of advanced hepatocellular carcinoma) before January 1, 2015 and remain to use them after the effective date of this Circular, they shall be entitled to 100% coverage. For cancer patients who used everolimus administered by injection or orally; L-asparaginase erwinia administered by injection; paclitaxel administered by injection in liposomal and polymeric micelle dosage form before January 1, 2019 and remain to use them after the effective date of this Circular; or sorafenib administered orally (for treatment of advanced renal cell carcinoma) after January 1, 2015 and remain to use them after the effective date of this Circular, they shall continue to be entitled to coverage by the health insurance fund at the rate specified in the Circular No. 40/2014/TT-BYT dated November 17, 2014 of the Minister of Health, introducing and providing instructions on the implementation of the Nomenclatures of modern drugs under the health insurance fund’s coverage. This regulation shall apply in the following cases:
a) A patient uses the aforesaid medications until the end of the treatment course (from the time of clinical diagnosis and start of the treatment to the time of end of treatment);
b) After being treated at a medical establishment, the patient is referred to another medical establishment, and is prescribed by a doctor to use the aforesaid medications within the course of treatment (except as he/she receives treatment provided by the out-of-network medical establishment);
c) With regard to the patient who has been recovered to a fairly stable state and allowed to end the treatment, if his/her health condition recurs, the doctor may prescribe him/her the previous medications to cure such recurring health condition;
d) During the course of treatment, the patient does not make a re-visit at the appointed time or does not take medicines regularly;
dd) The patient suffers side effects during use of erlotinib administered orally, or switches from use of erlotinib administered orally to use of gefitinib administered orally or vice versa as prescribed by the doctor because the medical establishment runs out of the medication in question.
Article 9. Reference clause
In case where referenced instruments mentioned in this Circular are replaced, revised or amended, the new or updated instruments shall govern.
In the course of implementation of this Circular, if there is any difficulty that arises, entities concerned should promptly inform the Ministry of Health (Department of Health Insurance) for its review and decision on possible actions./.
|
|
PP. MINISTER
DEPUTY MINISTER
Tran Van Thuan
|
APPENDIX I
Nomenclature of chemical medications and biologicals under health insurance policyholders’ received coverage
(enclosed with Circular No. 20/2022/TT-BYT dated December 31, 2022 of the Minister of Health of Vietnam)
Hospital classHospital classHospital class
1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS
1.1. Local anesthetics, general anesthetics1.1. Local anesthetics, general anesthetics1.1. Local anesthetics, general anesthetics1.1. Local anesthetics, general anesthetics1.1. Local anesthetics, general anesthetics1.1. Local anesthetics, general anesthetics
1.2. Muscle relaxants, reversal agents of muscle relaxants1.2. Muscle relaxants, reversal agents of muscle relaxants1.2. Muscle relaxants, reversal agents of muscle relaxants1.2. Muscle relaxants, reversal agents of muscle relaxants1.2. Muscle relaxants, reversal agents of muscle relaxants1.2. Muscle relaxants, reversal agents of muscle relaxants
2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM 2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM 2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM 2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM 2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM 2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM
2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)
2.2. Drugs for treatment of gout2.2. Drugs for treatment of gout2.2. Drugs for treatment of gout2.2. Drugs for treatment of gout2.2. Drugs for treatment of gout2.2. Drugs for treatment of gout
23. Anti-osteoarthritis drugs23. Anti-osteoarthritis drugs23. Anti-osteoarthritis drugs23. Anti-osteoarthritis drugs23. Anti-osteoarthritis drugs23. Anti-osteoarthritis drugs
2.4. Other drugs2.4. Other drugs2.4. Other drugs2.4. Other drugs2.4. Other drugs2.4. Other drugs
3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS
4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING
5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS
6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS 6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS 6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS 6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS 6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS 6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS
6.1. Anthelminthics6.1. Anthelminthics6.1. Anthelminthics6.1. Anthelminthics6.1. Anthelminthics6.1. Anthelminthics
6.2. Antibacterials6.2. Antibacterials6.2. Antibacterials6.2. Antibacterials6.2. Antibacterials6.2. Antibacterials
6.2.1. Drugs of beta-lactam group6.2.1. Drugs of beta-lactam group6.2.1. Drugs of beta-lactam group6.2.1. Drugs of beta-lactam group6.2.1. Drugs of beta-lactam group6.2.1. Drugs of beta-lactam group
6.2.2. Drugs of aminoglycoside group6.2.2. Drugs of aminoglycoside group6.2.2. Drugs of aminoglycoside group6.2.2. Drugs of aminoglycoside group6.2.2. Drugs of aminoglycoside group6.2.2. Drugs of aminoglycoside group
6.2.3. Drugs of phenicol group6.2.3. Drugs of phenicol group6.2.3. Drugs of phenicol group6.2.3. Drugs of phenicol group6.2.3. Drugs of phenicol group6.2.3. Drugs of phenicol group
6.2.4. Drugs of nitroimidazole group6.2.4. Drugs of nitroimidazole group6.2.4. Drugs of nitroimidazole group6.2.4. Drugs of nitroimidazole group6.2.4. Drugs of nitroimidazole group6.2.4. Drugs of nitroimidazole group
6.2.5. Drugs of lincosamide group6.2.5. Drugs of lincosamide group6.2.5. Drugs of lincosamide group6.2.5. Drugs of lincosamide group6.2.5. Drugs of lincosamide group6.2.5. Drugs of lincosamide group
6.2.6. Drugs of macrolide group6.2.6. Drugs of macrolide group6.2.6. Drugs of macrolide group6.2.6. Drugs of macrolide group6.2.6. Drugs of macrolide group6.2.6. Drugs of macrolide group
6.2.7. Drugs of quinolon group6.2.7. Drugs of quinolon group6.2.7. Drugs of quinolon group6.2.7. Drugs of quinolon group6.2.7. Drugs of quinolon group6.2.7. Drugs of quinolon group
6.2.8. Drugs of sulfamide group6.2.8. Drugs of sulfamide group6.2.8. Drugs of sulfamide group6.2.8. Drugs of sulfamide group6.2.8. Drugs of sulfamide group6.2.8. Drugs of sulfamide group
6.2.9. Drugs of tetracyclin group6.2.9. Drugs of tetracyclin group6.2.9. Drugs of tetracyclin group6.2.9. Drugs of tetracyclin group6.2.9. Drugs of tetracyclin group6.2.9. Drugs of tetracyclin group
6.2.10. Other drugs6.2.10. Other drugs6.2.10. Other drugs6.2.10. Other drugs6.2.10. Other drugs6.2.10. Other drugs
63. Antiviral drugs63. Antiviral drugs63. Antiviral drugs63. Antiviral drugs63. Antiviral drugs63. Antiviral drugs
63.1. Drugs for management of HIV/AIDS63.1. Drugs for management of HIV/AIDS63.1. Drugs for management of HIV/AIDS63.1. Drugs for management of HIV/AIDS63.1. Drugs for management of HIV/AIDS63.1. Drugs for management of HIV/AIDS
6.3.2. Hepatitis C medications6.3.2. Hepatitis C medications6.3.2. Hepatitis C medications6.3.2. Hepatitis C medications6.3.2. Hepatitis C medications6.3.2. Hepatitis C medications
6.3.3 Other antiviral drugs6.3.3 Other antiviral drugs6.3.3 Other antiviral drugs6.3.3 Other antiviral drugs6.3.3 Other antiviral drugs6.3.3 Other antiviral drugs
6.3.4. Drugs for treatment of COVID-19
6.4. Antifungal drugs6.4. Antifungal drugs6.4. Antifungal drugs6.4. Antifungal drugs6.4. Antifungal drugs6.4. Antifungal drugs
6.5. Drugs for treatment of amoebiasis 6.5. Drugs for treatment of amoebiasis 6.5. Drugs for treatment of amoebiasis 6.5. Drugs for treatment of amoebiasis 6.5. Drugs for treatment of amoebiasis 6.5. Drugs for treatment of amoebiasis
6.6. Drugs for treatment of tuberculosis 6.6. Drugs for treatment of tuberculosis 6.6. Drugs for treatment of tuberculosis 6.6. Drugs for treatment of tuberculosis 6.6. Drugs for treatment of tuberculosis 6.6. Drugs for treatment of tuberculosis
Drugs for treatment of drug-resistant tuberculosisDrugs for treatment of drug-resistant tuberculosisDrugs for treatment of drug-resistant tuberculosisDrugs for treatment of drug-resistant tuberculosisDrugs for treatment of drug-resistant tuberculosisDrugs for treatment of drug-resistant tuberculosis
6.7. Antimalarial drugs6.7. Antimalarial drugs6.7. Antimalarial drugs6.7. Antimalarial drugs6.7. Antimalarial drugs6.7. Antimalarial drugs
7. Drugs for treatment of migraine7. Drugs for treatment of migraine7. Drugs for treatment of migraine7. Drugs for treatment of migraine7. Drugs for treatment of migraine7. Drugs for treatment of migraine
8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS
8.1. Chemicals8.1. Chemicals8.1. Chemicals8.1. Chemicals8.1. Chemicals8.1. Chemicals
8.2. Targeted drugs8.2. Targeted drugs8.2. Targeted drugs8.2. Targeted drugs8.2. Targeted drugs8.2. Targeted drugs
83. Drugs for endocrine treatment83. Drugs for endocrine treatment83. Drugs for endocrine treatment83. Drugs for endocrine treatment83. Drugs for endocrine treatment83. Drugs for endocrine treatment
8.4. Immunosuppressive drugs8.4. Immunosuppressive drugs8.4. Immunosuppressive drugs8.4. Immunosuppressive drugs8.4. Immunosuppressive drugs8.4. Immunosuppressive drugs
8.5. Other drugs8.5. Other drugs8.5. Other drugs8.5. Other drugs8.5. Other drugs8.5. Other drugs
9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS
10. ANTIPARKINSONISM DRUGS10. ANTIPARKINSONISM DRUGS10. ANTIPARKINSONISM DRUGS10. ANTIPARKINSONISM DRUGS10. ANTIPARKINSONISM DRUGS10. ANTIPARKINSONISM DRUGS
11. BLOOD-AFFECTING DRUGS11. BLOOD-AFFECTING DRUGS11. BLOOD-AFFECTING DRUGS11. BLOOD-AFFECTING DRUGS11. BLOOD-AFFECTING DRUGS11. BLOOD-AFFECTING DRUGS
11.1. Antianaemia drugs11.1. Antianaemia drugs11.1. Antianaemia drugs11.1. Antianaemia drugs11.1. Antianaemia drugs11.1. Antianaemia drugs
11.2. Drugs affecting coagulation11.2. Drugs affecting coagulation11.2. Drugs affecting coagulation11.2. Drugs affecting coagulation11.2. Drugs affecting coagulation11.2. Drugs affecting coagulation
11.3. Blood and blood products11.3. Blood and blood products11.3. Blood and blood products11.3. Blood and blood products11.3. Blood and blood products11.3. Blood and blood products
11.4. Macromolecular solutions11.4. Macromolecular solutions11.4. Macromolecular solutions11.4. Macromolecular solutions11.4. Macromolecular solutions11.4. Macromolecular solutions
11.5. Other drugs11.5. Other drugs11.5. Other drugs11.5. Other drugs11.5. Other drugs11.5. Other drugs
12. Cardiovascular drugs12. Cardiovascular drugs12. Cardiovascular drugs12. Cardiovascular drugs12. Cardiovascular drugs12. Cardiovascular drugs
12.1. Antianginal drugs12.1. Antianginal drugs12.1. Antianginal drugs12.1. Antianginal drugs12.1. Antianginal drugs12.1. Antianginal drugs
12.2. Antiarrhythmic drugs12.2. Antiarrhythmic drugs12.2. Antiarrhythmic drugs12.2. Antiarrhythmic drugs12.2. Antiarrhythmic drugs12.2. Antiarrhythmic drugs
12.3. Antihypertensive drugs12.3. Antihypertensive drugs12.3. Antihypertensive drugs12.3. Antihypertensive drugs12.3. Antihypertensive drugs12.3. Antihypertensive drugs
12.4. Antihypotensive drugs12.4. Antihypotensive drugs12.4. Antihypotensive drugs12.4. Antihypotensive drugs12.4. Antihypotensive drugs12.4. Antihypotensive drugs
12.5. Drugs for treatment of heart failure12.5. Drugs for treatment of heart failure12.5. Drugs for treatment of heart failure12.5. Drugs for treatment of heart failure12.5. Drugs for treatment of heart failure12.5. Drugs for treatment of heart failure
12.6. Antithrombotic drugs12.6. Antithrombotic drugs12.6. Antithrombotic drugs12.6. Antithrombotic drugs12.6. Antithrombotic drugs12.6. Antithrombotic drugs
12.7. Hypolipidemic drugs12.7. Hypolipidemic drugs12.7. Hypolipidemic drugs12.7. Hypolipidemic drugs12.7. Hypolipidemic drugs12.7. Hypolipidemic drugs
12.8. Other drugs12.8. Other drugs12.8. Other drugs12.8. Other drugs12.8. Other drugs12.8. Other drugs
13. DERMATOLOGICAL DRUGS13. DERMATOLOGICAL DRUGS13. DERMATOLOGICAL DRUGS13. DERMATOLOGICAL DRUGS13. DERMATOLOGICAL DRUGS13. DERMATOLOGICAL DRUGS
14. DIAGNOSTIC AGENTS14. DIAGNOSTIC AGENTS14. DIAGNOSTIC AGENTS14. DIAGNOSTIC AGENTS14. DIAGNOSTIC AGENTS14. DIAGNOSTIC AGENTS
14.1. Ophthalmic drugs14.1. Ophthalmic drugs14.1. Ophthalmic drugs14.1. Ophthalmic drugs14.1. Ophthalmic drugs14.1. Ophthalmic drugs
14.2. Radiocontrast media14.2. Radiocontrast media14.2. Radiocontrast media14.2. Radiocontrast media14.2. Radiocontrast media14.2. Radiocontrast media
143. Other drugs143. Other drugs143. Other drugs143. Other drugs143. Other drugs143. Other drugs
15. DISINFECTANTS AND ANTISEPTICS15. DISINFECTANTS AND ANTISEPTICS15. DISINFECTANTS AND ANTISEPTICS15. DISINFECTANTS AND ANTISEPTICS15. DISINFECTANTS AND ANTISEPTICS15. DISINFECTANTS AND ANTISEPTICS
16. DIURETICS16. DIURETICS16. DIURETICS16. DIURETICS16. DIURETICS16. DIURETICS
17. GASTROINTESTINAL DRUGS17. GASTROINTESTINAL DRUGS17. GASTROINTESTINAL DRUGS17. GASTROINTESTINAL DRUGS17. GASTROINTESTINAL DRUGS17. GASTROINTESTINAL DRUGS
17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract
17.2. Antiemetics17.2. Antiemetics17.2. Antiemetics17.2. Antiemetics17.2. Antiemetics17.2. Antiemetics
17.3. Antispasmodic drugs17.3. Antispasmodic drugs17.3. Antispasmodic drugs17.3. Antispasmodic drugs17.3. Antispasmodic drugs17.3. Antispasmodic drugs
17.4. Laxatives17.4. Laxatives17.4. Laxatives17.4. Laxatives17.4. Laxatives17.4. Laxatives
17.5. Drug for treatment of diarrhoea17.5. Drug for treatment of diarrhoea17.5. Drug for treatment of diarrhoea17.5. Drug for treatment of diarrhoea17.5. Drug for treatment of diarrhoea17.5. Drug for treatment of diarrhoea
17.6. Drugs for treatment of haemorrhoids17.6. Drugs for treatment of haemorrhoids17.6. Drugs for treatment of haemorrhoids17.6. Drugs for treatment of haemorrhoids17.6. Drugs for treatment of haemorrhoids17.6. Drugs for treatment of haemorrhoids
17.7. Other drugs17.7. Other drugs17.7. Other drugs17.7. Other drugs17.7. Other drugs17.7. Other drugs
18. HORMONES AND ENDOCRINE MEDICINES18. HORMONES AND ENDOCRINE MEDICINES18. HORMONES AND ENDOCRINE MEDICINES18. HORMONES AND ENDOCRINE MEDICINES18. HORMONES AND ENDOCRINE MEDICINES18. HORMONES AND ENDOCRINE MEDICINES
18.1. Adrenal hormones and synthetic substitutes18.1. Adrenal hormones and synthetic substitutes18.1. Adrenal hormones and synthetic substitutes18.1. Adrenal hormones and synthetic substitutes18.1. Adrenal hormones and synthetic substitutes18.1. Adrenal hormones and synthetic substitutes
18.2. Androgen, estrogen, and progesteron products18.2. Androgen, estrogen, and progesteron products18.2. Androgen, estrogen, and progesteron products18.2. Androgen, estrogen, and progesteron products18.2. Androgen, estrogen, and progesteron products18.2. Androgen, estrogen, and progesteron products
18.3. Insulins and antidiabetic medicines18.3. Insulins and antidiabetic medicines18.3. Insulins and antidiabetic medicines18.3. Insulins and antidiabetic medicines18.3. Insulins and antidiabetic medicines18.3. Insulins and antidiabetic medicines
18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs
18.5. Drugs for treatment of diabetes insipidus18.5. Drugs for treatment of diabetes insipidus18.5. Drugs for treatment of diabetes insipidus18.5. Drugs for treatment of diabetes insipidus18.5. Drugs for treatment of diabetes insipidus18.5. Drugs for treatment of diabetes insipidus
18.6. Other drugs18.6. Other drugs18.6. Other drugs18.6. Other drugs18.6. Other drugs18.6. Other drugs
19. SERA AND IMMUNOGLOBULINS19. SERA AND IMMUNOGLOBULINS19. SERA AND IMMUNOGLOBULINS19. SERA AND IMMUNOGLOBULINS19. SERA AND IMMUNOGLOBULINS19. SERA AND IMMUNOGLOBULINS
20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS
21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS
21.1. Ophthalmological drugs21.1. Ophthalmological drugs21.1. Ophthalmological drugs21.1. Ophthalmological drugs21.1. Ophthalmological drugs21.1. Ophthalmological drugs
21.2. Otorhinolaryngological drugs21.2. Otorhinolaryngological drugs21.2. Otorhinolaryngological drugs21.2. Otorhinolaryngological drugs21.2. Otorhinolaryngological drugs21.2. Otorhinolaryngological drugs
22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS 22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS 22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS 22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS 22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS 22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS
22.1 Oxytocics and postpartum haemostatics22.1 Oxytocics and postpartum haemostatics22.1 Oxytocics and postpartum haemostatics22.1 Oxytocics and postpartum haemostatics22.1 Oxytocics and postpartum haemostatics22.1 Oxytocics and postpartum haemostatics
22.2. Antioxytocics 22.2. Antioxytocics 22.2. Antioxytocics 22.2. Antioxytocics 22.2. Antioxytocics 22.2. Antioxytocics
23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION
24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system
24.1. Sedative24.1. Sedative24.1. Sedative24.1. Sedative24.1. Sedative24.1. Sedative
24.2. Sporofic drugs24.2. Sporofic drugs24.2. Sporofic drugs24.2. Sporofic drugs24.2. Sporofic drugs24.2. Sporofic drugs
24.3. Antipsychotic drugs24.3. Antipsychotic drugs24.3. Antipsychotic drugs24.3. Antipsychotic drugs24.3. Antipsychotic drugs24.3. Antipsychotic drugs
24.4. Antidepressant drugs24.4. Antidepressant drugs24.4. Antidepressant drugs24.4. Antidepressant drugs24.4. Antidepressant drugs24.4. Antidepressant drugs
24.5 Drugs affecting nervous system24.5 Drugs affecting nervous system24.5 Drugs affecting nervous system24.5 Drugs affecting nervous system24.5 Drugs affecting nervous system24.5 Drugs affecting nervous system
25. DRUGS AFFECTING THE RESPIRATORY TRACT25. DRUGS AFFECTING THE RESPIRATORY TRACT25. DRUGS AFFECTING THE RESPIRATORY TRACT25. DRUGS AFFECTING THE RESPIRATORY TRACT25. DRUGS AFFECTING THE RESPIRATORY TRACT25. DRUGS AFFECTING THE RESPIRATORY TRACT
25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease 25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease 25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease 25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease 25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease 25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease
25.2. Antitussives25.2. Antitussives25.2. Antitussives25.2. Antitussives25.2. Antitussives25.2. Antitussives
25.3. Other drugs25.3. Other drugs25.3. Other drugs25.3. Other drugs25.3. Other drugs25.3. Other drugs
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION
26.1. Oral medicines26.1. Oral medicines26.1. Oral medicines26.1. Oral medicines26.1. Oral medicines26.1. Oral medicines
26.2. Drugs for infusion26.2. Drugs for infusion26.2. Drugs for infusion26.2. Drugs for infusion26.2. Drugs for infusion26.2. Drugs for infusion
26.3. Other drugs26.3. Other drugs26.3. Other drugs26.3. Other drugs26.3. Other drugs26.3. Other drugs
27. MINERALS AND VITAMINS27. MINERALS AND VITAMINS27. MINERALS AND VITAMINS27. MINERALS AND VITAMINS27. MINERALS AND VITAMINS27. MINERALS AND VITAMINS
|
No
|
Name of active ingredient
|
Route of administration, dosage form
|
Hospital class
|
Note |
|
|
|
(1)
|
(2)
|
(3)
|
(4)
|
(5)
|
(6)
|
(7)
|
(8)
|
|
|
|
|
1. LOCAL ANESTHETICS, GENERAL ANESTHETICS, MUSCLE RELAXANTS, REVERSAL AGENTS OF MUSCLE RELAXANTS
|
|
|
|
|
1.1. Local anesthetics, general anesthetics
|
|
|
|
1
|
Atropin sulfate
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
2
|
Bupivacaine hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
3
|
Desflurane
|
Inhalation
|
+
|
+
|
+
|
|
|
|
|
|
4
|
Dexmedetomidine
|
Injection
|
+
|
+
|
|
|
|
|
|
|
5
|
Diazepam
|
Injection
|
+
|
+
|
+
|
+
|
For general clinics and commune health stations: costs of emergency care services shall be covered by the health insurance fund.
|
|
|
|
6
|
Etomidate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
7
|
Fentanyl
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
8
|
Halothane
|
Respiratory route
|
+
|
+
|
+
|
|
|
|
|
|
9
|
Isoflurane
|
Respiratory route
|
+
|
+
|
+
|
|
|
|
|
|
10
|
Ketamine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
11
|
Levobupivacaine
|
Injection
|
+
|
+
|
|
|
|
|
|
|
12
|
Lidocaine hydrochloride
|
Injection, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Nebules
|
+
|
+
|
+
|
|
|
|
|
|
13
|
Lidocaine + epinephrine (adrenaline)
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
14
|
Lidocaine + prilocaine
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
15
|
Midazolam
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
16
|
Morphine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
17
|
Medicinal oxygen
|
Respiratory route, liquefied or compressed gas
|
+
|
+
|
+
|
+
|
|
|
|
|
18
|
Pethidine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
19
|
Procaine hydrochloride
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
20
|
Proparacaine hydrochloride
|
Injection, eye drops
|
+
|
+
|
|
|
|
|
|
|
21
|
Propofol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
22
|
Ropivacaine hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
23
|
Sevoflurane
|
Respiratory route, Nebules
|
+
|
+
|
+
|
|
|
|
|
|
24
|
Sufentanil
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
25
|
Sodium thiopental
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
|
1.2. Muscle relaxants, reversal agents of muscle relaxants
|
|
|
|
26
|
Atracurium besylate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
27
|
Neostigmine methylsulfate (bromide)
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
28
|
Pancuronium bromide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
29
|
Pipecuronium bromide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
30
|
Rocuronium bromide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
31
|
Suxamethonium chloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
32
|
Vecuronium bromide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
|
2. ANALGESIC DRUGS, NON-STEROID ANTIPHLOGISTIC DRUGS; DRUGS FOR TREATMENT OF GOUT AND RHEUMATISM
|
|
|
|
|
2.1. Analgesic and antipyretic agents, non-steroidal anti-inflammatory drugs (NSAID)
|
|
|
|
33
|
Aceclofenac
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
34
|
Aescin
|
Injection, oral administration
|
+
|
+
|
|
|
|
|
|
|
35
|
Celecoxib
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
36
|
Dexibuprofen
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
37
|
Diclofenac
|
Injection, eye drops
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, Topical administration, rectal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
38
|
Etodolac
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
39
|
Etoricoxib
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
40
|
Fentanyl
|
Transdermal patch
|
+
|
+
|
+
|
|
Costs of cancer pain management shall be covered by the Health insurance fund.
|
|
|
|
41
|
Floctafenine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
42
|
Flurbiprofen Sodium
|
Oral administration, suppositories
|
+
|
+
|
+
|
|
|
|
|
|
43
|
Ibuprofen
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
44
|
Ibuprofen + codeine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
45
|
Ketoprofen
|
Injection, Transdermal patch
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
46
|
Ketorolac
|
Injection, oral administration, eye drops
|
+
|
+
|
+
|
|
|
|
|
|
47
|
Loxoprofen
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
48
|
Meloxicam
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
49
|
Methyl salicylate + dl-camphor + thymol + l-menthol + glycol salicylate + tocopherol acetate
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
50
|
Morphine
|
Injection
|
+
|
+
|
+
|
+
|
For general clinics and commune health stations: Costs of emergency care services shall be covered by the health insurance fund.
|
|
|
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
51
|
Nabumetone
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
52
|
Naproxen
|
Oral administration, suppositories
|
+
|
+
|
+
|
|
|
|
|
|
53
|
Naproxen + esomeprazole
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
54
|
Nefopam hydrochloride
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
55
|
Oxycodone
|
Oral administration
|
+
|
|
|
|
50% of costs of cancer pain management shall be covered by the Health insurance fund;
|
|
|
|
56
|
Paracetamol (acetaminophen)
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, suppositories
|
+
|
+
|
+
|
+
|
|
|
|
57
|
Paracetamol + chlorpheniramine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
58
|
Paracetamol + codeine phosphate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
59
|
Paracetamol + diphenhydramine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
60
|
Paracetamol + ibuprofen
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
61
|
Paracetamol + methocarbamol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
62
|
Paracetamol + phenylephrine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
63
|
Paracetamol + pseudoephedrine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
64
|
Paracetamol + tramadol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
65
|
Paracetamol + chlorpheniramine + dextromethorphan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
66
|
Paracetamol + chlorpheniramine + phenylephrine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
67
|
Paracetamol + chlorpheniramine + pseudoephedrine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
68
|
Paracetamol + diphenhydramine + phenylephrine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
69
|
Paracetamol + phenylephrine + dextromethorphan
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
70
|
Paracetamol + chlorpheniramine + phenylephrine + dextromethorphan
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
71
|
Pethidine hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
72
|
Piroxicam
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
73
|
Tenoxicam
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
74
|
Tiaprofenic acid
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
75
|
Tramadol
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
2.2. Drugs for treatment of gout
|
|
|
|
76
|
Allopurinol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
77
|
Colchicine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
78
|
Probenecid
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
23. Anti-osteoarthritis drugs
|
|
|
|
79
|
Diacerein
|
Oral administration
|
+
|
+
|
+
|
|
Costs of management of knee or hip osteoarthritis shall be covered by the Health insurance fund.
|
|
|
|
80
|
Glucosamine
|
Oral administration
|
+
|
+
|
+
|
|
Costs of management of mild and moderate knee osteoarthritis shall be covered by the Health insurance fund.
|
|
|
|
|
2.4. Other drugs
|
|
|
|
81
|
Adalimumab
|
Injection
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
82
|
Alendronate
|
Oral administration
|
+
|
|
|
|
Cost of management of osteoporosis at the Central Geriatric Hospital and the musculoskeletal department of special class hospital or class I hospital shall be covered by the health insurance fund.
|
|
|
|
83
|
Alendronate sodium + cholecalciferol (vitamin D3)
|
Oral administration
|
+
|
|
|
|
Cost of management of osteoporosis at the Central Geriatric Hospital and the musculoskeletal department of special class hospital or class I hospital shall be covered by the health insurance fund.
|
|
|
|
84
|
Alpha chymotrypsin
|
Oral administration
|
+
|
+
|
+
|
+
|
Costs of drugs for treatment of edema after surgery, injuries, burns shall be covered by the Health insurance fund.
|
|
|
|
85
|
Calcitonin
|
Injection
|
+
|
+
|
+
|
|
Costs shall be covered by the Health insurance fund:
- Costs of prevention of acute bone loss due to sudden immobilization as in the case of patients with osteoporosis fractures;
- Costs of drugs for treatment of Paget's disease for patients who do not respond to other treatments or are not suitable for other treatments, such as patients with severe impairment of kidney function;
- Costs of drugs for treatment of malignant hypercalcemia.
|
|
|
|
86
|
Etanercept
|
Injection
|
+
|
+
|
|
|
30% of costs shall be covered by the Health insurance fund.
|
|
|
|
87
|
Golimumab
|
Injection
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund.
|
|
|
|
88
|
Infliximab
|
Infusion
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund.
|
|
|
|
89
|
Leflunomide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
90
|
Methocarbamol
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
91
|
Risedronate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
92
|
Tocilizumab
|
Injection
|
+
|
|
|
|
Costs of drugs for treatment shall be covered by the Health Insurance fund in one of the following cases:
- The indications include use at special and class I hospitals and musculoskeletal departments of class II hospitals, in which case 60% of costs shall be covered;
- The drug is used for treatment of COVID-19 according to the Ministry of Health's COVID-19 diagnosis and treatment guidelines.
|
|
|
|
93
|
Zoledronic acid
|
Injection
|
+
|
+
|
|
|
Costs shall be covered by the Health insurance fund:
- Costs of drugs for treatment of bone metastasis at special class, class I, II hospitals;
- Costs of drugs for treatment of osteoporosis at the National Geriatric Hospital and musculoskeletal departments of special class, class I hospitals.
|
|
|
|
|
3. ANTIALLERGICS AND ANAPHYLAXIS MEDICATIONS
|
|
|
|
94
|
Alimemazine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
95
|
Bilastine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
96
|
Cetirizine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
97
|
Cinnarizine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
98
|
Chlorpheniramine (hydrogen maleate)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
99
|
Chlorpheniramine + dextromethorphan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
100
|
Chlorpheniramine + phenylephrine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
101
|
Desloratadine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
102
|
Dexchlorpheniramine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
103
|
Diphenhydramine
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
104
|
Ebastine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
105
|
Epinephrine (adrenaline)
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
106
|
Fexofenadine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
107
|
Ketotifen
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Eye drops
|
+
|
+
|
|
|
|
|
|
108
|
Levocetirizine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
109
|
Loratadine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
110
|
Loratadine + pseudoephedrine
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
111
|
Mequitazine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
112
|
Promethazine hydrochloride
|
Injection, oral administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
113
|
Rupatadine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
4. ANTIDOTES AND DRUGS USED IN CASE OF POISONING
|
|
|
|
114
|
Acetylcysteine
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
115
|
Atropine
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
116
|
Calcium gluconate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
117
|
Dantrolene
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
118
|
Deferoxamine
|
Oral administration, injection
|
+
|
+
|
+
|
|
|
|
|
|
119
|
Dimercaprol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
120
|
Sodium calcium edentate (sodium calcium EDTA)
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
121
|
Ephedrine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
122
|
Esmolol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
123
|
Flumazenil
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
124
|
Fomepizole
|
Injection
|
+
|
+
|
|
|
|
|
|
|
125
|
Glucagon
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
126
|
Glutathione
|
Injection
|
+
|
+
|
|
|
50% of costs for radiation therapy, costs of cancer treatment with cisplatin or carboplatin;
|
|
|
|
127
|
Hydroxocobalamin
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
128
|
Calcium folinate (folinic acid, leucovorin)
|
Injection, oral administration
|
+
|
+
|
|
|
|
|
|
|
129
|
Naloxone hydrochloride
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
130
|
Naltrexone
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
131
|
Sodium hydrogencarbonate (sodium bicarbonate)
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
132
|
Sodium nitrite
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of cyanide poisoning shall be covered by the Health insurance fund.
|
|
|
|
133
|
Sodium thiosulfate
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
134
|
Norepinephrine (noradrenaline)
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
135
|
Penicilamine
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
136
|
Phenylephrine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
137
|
Polystyrene
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Enema
|
+
|
+
|
|
|
|
|
|
138
|
Pralidoxime
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
139
|
Protamine sulfate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
140
|
Meglumine sodium succinate
|
Infusion
|
+
|
+
|
|
|
|
|
|
|
141
|
Sorbitol
|
Washing solution
|
+
|
+
|
+
|
+
|
|
|
|
|
142
|
Silibinin
|
Injection
|
+
|
+
|
|
|
Costs of drugs for treatment of mushroom poisoning shall be covered by the Health insurance fund.
|
|
|
|
143
|
Succimer
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment of lead poisoning shall be covered by the Health insurance fund.
|
|
|
|
144
|
Sugammadex
|
Injection
|
+
|
|
|
|
Costs of drugs for treatment shall be covered by the Health Insurance fund for:
1. Patients who have been injected with muscle relaxants without intubation;
2. Patients with chronic obstructive pulmonary disease (COPD), bronchial asthma;
3. Patients with heart failure, arrhythmia, valvular heart disease, coronary artery;
4. Patients with obesity (BMI > 30);
5. Patients with neuromuscular pathologies (muscular dystrophy, myasthenia gravis);
6. Patient who have contraindications to neostigmine and atropine.
|
|
|
|
145
|
Activated carbon
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
146
|
Activated carbon + sorbitol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
147
|
Methylene blue
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
|
5. ANTICONVULSANT, ANTIEPILEPTIC DRUGS
|
|
|
|
148
|
Carbamazepine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
149
|
Gabapentin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
150
|
Lamotrigine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
151
|
Levetiracetam
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and psychiatric hospitals.
|
|
|
|
152
|
Oxcarbazepine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
153
|
Phenobarbital
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
154
|
Phenytoin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
155
|
Pregabalin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
156
|
Topiramate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
157
|
Valproate sodium
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
158
|
Valproate sodium + valproic acid
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
159
|
Valproic acid
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
|
6. ANTI-PARASITIC, ANTIBACTERIAL DRUGS
|
|
|
|
|
6.1. Anthelminthics
|
|
|
|
160
|
Albendazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
161
|
Diethylcarbamazine (dihydrogen citrate)
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
162
|
Ivermectin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
163
|
Mebendazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
164
|
Niclosamide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
165
|
Praziquantel
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
166
|
Pyrantel
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
167
|
Triclabendazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.2. Antibacterials
|
|
|
|
|
6.2.1. Drugs of beta-lactam group
|
|
|
|
168
|
Amoxicillin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
169
|
Amoxicillin + clavulanic acid
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
170
|
Amoxicillin + sulbactam
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of otitis media or community-acquired pneumonia.
|
|
|
|
171
|
Ampicillin (sodium salt)
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
172
|
Ampicillin + sulbactam
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
173
|
Benzathine benzylpenicillin
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
174
|
Benzylpenicillin
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
175
|
Cefaclor
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
176
|
Cefadroxil
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
177
|
Cefalexin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
178
|
Cefalothin
|
Injection
|
+
|
|
|
|
|
|
|
|
179
|
Cefamandol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
180
|
Cefazolin
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
181
|
Cefdinir
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
182
|
Cefepime
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
183
|
Cefixime
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
184
|
Cefmetazol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
185
|
Cefoperazone
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
186
|
Cefoperazone + sulbactam
|
Injection
|
+
|
+
|
|
|
|
|
|
|
187
|
Cefotaxime
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
188
|
Cefotiam
|
Injection
|
+
|
+
|
|
|
|
|
|
|
189
|
Cefoxitin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
190
|
Cefpirom
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
191
|
Cefpodoxime
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
192
|
Cefradine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
193
|
Ceftazidime
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
194
|
Ceftazidime + avibactam
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided for patients who are treated for COVID-19 according to the Ministry of Health's COVID-19 diagnosis and treatment guidelines.
|
|
|
|
195
|
Ceftibuten
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
196
|
Ceftizoxime
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
197
|
Ceftolozan + tazobactam
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided for patients who are treated for COVID-19 according to the Ministry of Health's COVID-19 diagnosis and treatment guidelines.
|
|
|
|
198
|
Ceftriaxone
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
199
|
Cefuroxime
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
200
|
Cloxacillin
|
Injection, Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
201
|
Doripenem*
|
Injection
|
+
|
+
|
|
|
|
|
|
|
202
|
Ertapenem*
|
Injection
|
+
|
+
|
|
|
|
|
|
|
203
|
Imipenem + cilastatin*
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
204
|
Meropenem*
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
205
|
Oxacillin
|
Injection, Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
206
|
Piperacillin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
207
|
Piperacillin + tazobactam
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
208
|
Phenoxy methylpenicillin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
209
|
Procain benzylpenicillin
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
210
|
Sultamicillin
(Ampicillin + sulbactam)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
211
|
Ticarcillin + clavulanic acid
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
|
6.2.2. Drugs of aminoglycoside group
|
|
|
|
212
|
Amikacin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
213
|
Gentamicin
|
Injection, ophthalmic administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
214
|
Neomycin (sulfate)
|
Oral administration, Eye drops, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
215
|
Neomycin + polymyxin B
|
Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
216
|
Neomycin + polymyxin B + dexamethasone
|
Eye drops, ear drops
|
+
|
+
|
+
|
+
|
|
|
|
|
217
|
Netilmicin sulfate
|
Injection
|
+
|
+
|
|
|
|
|
|
|
218
|
Tobramycin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
219
|
Tobramycin + dexamethasone
|
Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.2.3. Drugs of phenicol group
|
|
|
|
220
|
Cloramphenicol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.2.4. Drugs of nitroimidazole group
|
|
|
|
221
|
Metronidazole
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, topical administration, vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
222
|
Metronidazole + neomycin + nystatin
|
Vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
223
|
Secnidazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
224
|
Tinidazole
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.2.5. Drugs of lincosamide group
|
|
|
|
225
|
Clindamycin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.2.6. Drugs of macrolide group
|
|
|
|
226
|
Azithromycin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
227
|
Clarithromycin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
228
|
Erythromycin
|
Oral administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
229
|
Roxithromycin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
230
|
Spiramycin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
231
|
Spiramycin + metronidazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
232
|
Tretinoin + erythromycin
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
|
6.2.7. Drugs of quinolon group
|
|
|
|
233
|
Ciprofloxacin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, Eye drops, ear drops
|
+
|
+
|
+
|
+
|
|
|
|
|
234
|
Levofloxacin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Oral administration, Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
235
|
Lomefloxacin
|
Oral administration, Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
236
|
Moxifloxacin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Oral administration, Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
237
|
Nalidixic acid
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
238
|
Norfloxacin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
239
|
Ofloxacin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, Eye drops, ear drops
|
+
|
+
|
+
|
+
|
|
|
|
|
240
|
Pefloxacin
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
6.2.8. Drugs of sulfamide group
|
|
|
|
241
|
Silver sulfadiazine
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
242
|
Sulfadimidine (sodium salt)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
243
|
Sulfadoxin + pyrimethamine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
244
|
Sulfaguanidine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
245
|
Sulfamethoxazole + trimethoprim
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
246
|
Sulfasalazine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
6.2.9. Drugs of tetracyclin group
|
|
|
|
247
|
Doxycycline
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
248
|
Minocycline
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
249
|
Tigecycline*
|
Injection
|
+
|
|
|
|
Coverage shall be provided by the Health insurance fund if the initial antibiotic regimen is ineffective in treatment of abdominal infections, skin infections, soft tissue complications.
|
|
|
|
250
|
Tetracycline hydrochloride
|
Oral administration, ophthalmic administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.2.10. Other drugs
|
|
|
|
251
|
Argyrol
|
Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
252
|
Colistin*
|
Injection
|
+
|
+
|
|
|
|
|
|
|
253
|
Daptomycin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
254
|
Fosfomycin*
|
Injection, Oral administration, ear drops
|
+
|
+
|
|
|
|
|
|
|
255
|
Linezolid*
|
Oral administration, injection
|
+
|
+
|
|
|
|
|
|
|
256
|
Nitrofurantoin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
257
|
Rifampicin
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Eye drops, ear drops
|
+
|
+
|
+
|
|
|
|
|
|
258
|
Teicoplanin*
|
Injection
|
+
|
+
|
|
|
|
|
|
|
259
|
Vancomycin
|
Injection
|
+
|
+
|
|
|
Coverage shall be provided by the Health insurance fund at special class, class I, class II hospitals and hospitals specialized in treatment for tuberculosis and lung diseases.
|
|
|
|
|
63. Antiviral drugs
|
|
|
|
|
63.1. Drugs for management of HIV/AIDS
|
|
|
|
260
|
Abacavir (ABC)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
261
|
Darunavir
|
Oral administration
|
+
|
+
|
+
|
|
Costs of management of HIV/AIDS shall be covered by the Health insurance fund in case drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
262
|
Efavirenz (EFV hoặc EFZ)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
263
|
Lamivudine
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
264
|
Nevirapine (NVP)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
265
|
Raltegravir
|
Oral administration
|
+
|
+
|
+
|
|
Costs of management of HIV/AIDS shall be covered by the Health insurance fund in case drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
266
|
Ritonavir
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
267
|
Tenofovir (TDF)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
268
|
Zidovudine (ZDV hoặc AZT)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
269
|
Lamivudine + tenofovir
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
270
|
Lamivudine+ zidovudin
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
271
|
Lopinavir + ritonavir (LPV/r)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
272
|
Tenofovir + lamivudine + efavirenz
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
273
|
Tenoforvir + lamivudine + dolutegravir
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
274
|
Zidovudine (ZDV hoặc AZT) + lamivudine + nevirapine (NVP)
|
Oral administration
|
+
|
+
|
+
|
|
Regarding management of HIV/AIDS: Drugs are dispensed at commune health stations according to the management, treatment and care guidelines of the Ministry of Health.
|
|
|
|
|
6.3.2. Hepatitis C medications
|
|
|
|
275
|
Daclatasvir
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund.
|
|
|
|
276
|
Sofosbuvir
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
277
|
Sofosbuvir + ledipasvir
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
278
|
Sofosbuvir + velpatasvir
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
279
|
Pegylated interferon (peginterferon) alpha
(2a or 2b)
|
Injection
|
+
|
+
|
|
|
30% of costs of drugs for hepatitis C treatment shall be covered by the Health insurance fund according to the diagnostic and treatment guidelines of the Ministry of Health in case direct acting antivirals (DAAs) cannot be used;
|
|
|
|
|
6.3.3 Other antiviral drugs
|
|
|
|
280
|
Aciclovir
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, ophthalmic administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
281
|
Entecavir
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
282
|
Gancyclovir*
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
283
|
Oseltamivir
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of influenza virus infection shall be covered by the Health insurance fund.
|
|
|
|
284
|
Ribavirin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
285
|
Valganciclovir*
|
Oral administration
|
+
|
|
|
|
50% of costs of drugs for treatment of reactivated cytomegalovirus (CMV) diseases for patients who have organ transplants or stem cell transplants shall be covered by the Health insurance fund.
|
|
|
|
286
|
Zanamivir
|
Inhalation
|
+
|
|
|
|
|
|
|
|
|
6.3.4. Drugs for treatment of COVID-19
|
|
|
|
|
|
|
|
|
287
|
Molnupiravir
|
Oral administration
|
+
|
+
|
+
|
|
Coverage shall be provided for patients who are treated for COVID-19 according to the Ministry of Health's COVID-19 diagnosis and treatment guidelines.
|
|
|
|
|
6.4. Antifungal drugs
|
|
|
|
288
|
Amphotericin B*
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Lipid complex
|
+
|
|
|
|
Costs of drugs shall be covered by the Health Insurance fund in the following cases:
- Drugs used for treatment of severe invasive candidiasis;
- Drugs used for treatment of severe systemic mycosis for patients who do not respond to conventional amphotericin B or do not respond to other systemic antifungals, or for patients with renal impairment, or for patients taking conventional forms with progression of renal failure, or contraindications other than the usual form.
|
|
|
|
289
|
Anidulafungin
|
Injection
|
+
|
|
|
|
Coverage shall be provided for patients who are treated for COVID-19 according to the Ministry of Health's COVID-19 diagnosis and treatment guidelines.
|
|
|
|
290
|
Butoconazole nitrate
|
Vaginal cream
|
+
|
+
|
|
|
|
|
|
|
291
|
Caspofungin*
|
Injection
|
+
|
|
|
|
Costs of drugs shall be covered by the Health Insurance fund in the following cases:
- Drugs used for empirical treatment of invasive fungal infections (Candida or Aspergilus) for high-risk patients with fever, neutropenia;
- Drugs used for treatment of invasive Candida fungal infections;
- Drugs used for treatment of invasive Aspergillus fungal infections in patients who are refractory to or intolerant of other therapies.
|
|
|
|
292
|
Ciclopiroxolamine
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
293
|
Clotrimazole
|
Vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
294
|
Dequalinium chloride
|
Vaginal suppositories
|
+
|
+
|
|
|
|
|
|
|
295
|
Econazole
|
Topical administration, vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
296
|
Fluconazole
|
Infusion, Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
297
|
Fenticonazole nitrate
|
Vaginal suppositories, topical administration
|
+
|
+
|
+
|
|
|
|
|
|
298
|
Flucytosine
|
Injection
|
+
|
+
|
|
|
|
|
|
|
299
|
Griseofulvin
|
Oral administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
300
|
Ifraconazole
|
Infusion
|
+
|
+
|
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
301
|
Ketoconazole
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
Topical administration, vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
302
|
Micafungin
|
Injection
|
+
|
|
|
|
Coverage shall be provided for patients who are treated for COVID-19 according to the Ministry of Health's COVID-19 diagnosis and treatment guidelines.
|
|
|
|
303
|
Miconazole
|
Topical administration, vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
304
|
Natamycin
|
Eye drops, topical administration, vaginal suppositories
|
+
|
+
|
+
|
|
|
|
|
|
305
|
Nystatin
|
Oral administration, vaginal suppositories, thrush powder
|
+
|
+
|
+
|
+
|
|
|
|
|
306
|
Policresulen
|
Vaginal suppositories
|
+
|
+
|
+
|
|
|
|
|
|
307
|
Posaconazole*
|
Oral administration
|
+
|
|
|
|
50% of costs of drugs shall be covered by the Health Insurance fund in the following cases:
- Drugs used for trearment of Fusarium fungal infections, Zygomycetes fungal infections, cryptococcal mycosis, colored mycosis and fungal tumors for patients with diseases refractory to other drugs or patients intolerant to other drugs;
- Drugs used for treatment of Coccidioidomycosis, treatment of Coccidioidomycosis failed or treatment of Coccidioidomycosis which is intolerant to other antifungal drugs.
|
|
|
|
308
|
Terbinafine (hydrochloride)
|
Oral administration, topical administration
|
+
|
+
|
+
|
|
|
|
|
|
309
|
Voriconazole*
|
Oral administration
|
+
|
|
|
|
50% of costs of drugs for treatment of the following diseases shall be covered by the Health insurance fund:
- Invasive Aspergillosis;
- Cadidemia in non-aleukemia patients;
- Fluconazole-resistant severe invasive candidiasis;
- Severe fungal infections caused by Scedosporium spp. and Fusarium spp. in patients who do not respond to other treatments.
|
|
|
|
310
|
Clotrimazole + betamethasone
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
311
|
Clorquinaldol + promestriene
|
Vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
312
|
Miconazole + hydrocortisone
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
313
|
Nystatin + metronidazole + neomycin
|
Vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
314
|
Nystatin + neomycin + polymyxin B
|
Vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.5. Drugs for treatment of amoebiasis
|
|
|
|
315
|
Diiodohydroxyquinoline
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
316
|
Hydroxy chloroquine
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
317
|
Metronidazole
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
6.6. Drugs for treatment of tuberculosis
|
|
|
|
318
|
Ethambutol
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
319
|
Isoniazid
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
320
|
Isoniazid + ethambutol
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
321
|
Pyrazinamide
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
322
|
Rifampicin
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
323
|
Rifampicin + isoniazid
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
324
|
Rifampicin + isoniazid + pyrazinamide
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
325
|
Rifampicin + isoniazid + pyrazinamide + ethambutol
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
326
|
Streptomycin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
|
Drugs for treatment of drug-resistant tuberculosis
|
|
|
|
327
|
Amikacin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
328
|
Bedaquiline
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of drug-resistant tuberculosis shall be covered by the Health insurance fund; Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health;
|
|
|
|
329
|
Capreomycin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
330
|
Clofazimine
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of drug-resistant tuberculosis shall be covered by the Health insurance fund; Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health;
|
|
|
|
331
|
Cycloserine
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
332
|
Delamanid
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of drug-resistant tuberculosis shall be covered by the Health insurance fund; Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health;
|
|
|
|
333
|
Ethionamide
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
334
|
Kanamycin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
255
|
Linezolid*
|
Oral administration
|
+
|
+
|
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
234
|
Levofloxacin
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
236
|
Moxifloxacin
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health.
|
|
|
|
335
|
PAS- Na
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of drug-resistant tuberculosis shall be covered by the Health insurance fund; Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health;
|
|
|
|
336
|
Prothionamide
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of drug-resistant tuberculosis shall be covered by the Health insurance fund; Drugs are dispensed at commune health stations according to the guidelines for diagnosis, treatment and prevention of tuberculosis of the Ministry of Health;
|
|
|
|
|
6.7. Antimalarial drugs
|
|
|
|
337
|
Artesunate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
338
|
Chloroquine
|
Injection, Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
339
|
Piperaquin + dihydroartemisinin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
340
|
Primaquine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
341
|
Quinine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
7. Drugs for treatment of migraine
|
|
|
|
342
|
Dihydro ergotamine mesylate
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
343
|
Ergotamine (tartrate)
|
Injection, Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
344
|
Flunarizine
|
Oral administration
|
+
|
+
|
+
|
+
|
Costs of drugs for preventive treatment of migraines shall be covered by the Health insurance fund if other treatments are ineffective or patients are intolerant of other treatments.
|
|
|
|
345
|
Sumatriptan
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
8. ANTINEOPLASTIC AND IMMUNOSUPPRESSIVE DRUGS
|
|
|
|
|
8.1. Chemicals
|
|
|
|
346
|
Arsenic trioxide
|
Injection
|
+
|
+
|
|
|
|
|
|
|
347
|
Bendamustine
|
Infusion
|
+
|
+
|
|
|
50% of costs of drugs for treatment of lymphocytic leukemia stage B/C unsuitable for chemotherapy with Fludarabine; slow-growing non-Hodgkin's lymphoma in patients who have progressed after treatment with Rituximab.
|
|
|
|
348
|
Bleomycin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
349
|
Bortezomib
|
Injection
|
+
|
+
|
|
|
|
|
|
|
350
|
Busulfan
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
351
|
Capecitabine
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
352
|
Carboplatin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
353
|
Carmustine
|
Injection
|
+
|
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
354
|
Cisplatin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
355
|
Cyclophosphamide
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
356
|
Cytarabine
|
Injection
|
+
|
+
|
|
|
|
|
|
|
357
|
Dacarbazine
|
Injection
|
+
|
|
|
|
|
|
|
|
358
|
Dactinomycin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
359
|
Daunorubicin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
360
|
Decitabine
|
Injection
|
+
|
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
361
|
Docetaxel
|
Injection
|
+
|
+
|
|
|
|
|
|
|
362
|
Doxorubicin
|
Injection
|
+
|
+
|
|
|
50% of costs of liposome-encapsulated doxorubicin shall be covered by the Health insurance fund; 100% of costs of unencapsulated doxorubicin shall be covered by the Health insurance fund.
|
|
|
|
363
|
Epirubicin hydrochloride
|
Injection
|
+
|
+
|
|
|
|
|
|
|
364
|
Etoposide
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
365
|
Everolimus
|
Injection, Oral administration
|
+
|
+
|
|
|
50% of costs of Everolimus used for treatment of cancer shall be covered by the Health insurance fund; 100% of costs of Everolimus used for treatment of other diseases shall be covered by the Health insurance fund.
|
|
|
|
366
|
Fludarabine
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
367
|
Fluorouracil (5-FU)
|
Injection, topical administration
|
+
|
+
|
|
|
|
|
|
|
368
|
Gemcitabine
|
Injection
|
+
|
+
|
|
|
|
|
|
|
369
|
Hydroxyurea (Hydroxycarbamide)
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
370
|
Idarubicin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
371
|
Ifosfamide
|
Injection
|
+
|
+
|
|
|
|
|
|
|
372
|
Irinotecan
|
Injection
|
+
|
+
|
|
|
|
|
|
|
373
|
L-asparaginase
|
Injection
|
+
|
+
|
|
|
50% of costs of L-asparaginase in the form of L-asparaginase erwinia shall be covered by the Health insurance fund; 100% of costs of L-asparaginase in the other forms shall be covered by the Health insurance fund.
|
|
|
|
374
|
Melphalan
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
375
|
Mercaptopurine
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
376
|
Mesna
|
Injection
|
+
|
+
|
|
|
|
|
|
|
377
|
Methotrexate
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
378
|
Mitomycin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
379
|
Mitoxantrone
|
Injection
|
+
|
+
|
|
|
|
|
|
|
380
|
Oxaliplatin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
381
|
Paclitaxel
|
Injection
|
+
|
+
|
|
|
50% of costs of Paclitaxel encapsulated in liposome and polymeric micelle shall be covered by the Health insurance fund; 100% of costs of Paclitaxel encapsulated in other form shall be covered by the Health insurance fund.
|
|
|
|
382
|
Pemetrexed
|
Injection
|
+
|
|
|
|
50% of costs of drugs for treatment of non-small cell lung cancer and malignant pleural mesothelioma shall be covered by the Health insurance fund;
|
|
|
|
383
|
Procarbazine
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
384
|
Tegafur-uracil (UFT hoặc UFUR)
|
Oral administration
|
+
|
|
|
|
|
|
|
|
385
|
Tegafur + gimeracil + oteracil potassium
|
Oral administration
|
+
|
+
|
|
|
70% of costs of drugs for treatment of metastatic gastric cancer shall be covered by the Health insurance fund;
|
|
|
|
386
|
Temozolomide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
387
|
Tretinoin (All-trans retinoic acid)
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
388
|
Vinblastine sulfate
|
Injection
|
+
|
+
|
|
|
|
|
|
|
389
|
Vincristine sulfate
|
Injection
|
+
|
+
|
|
|
|
|
|
|
390
|
Vinorelbine
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
|
8.2. Targeted drugs
|
|
|
|
391
|
Afatinib dimaleate
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
392
|
Bevacizumab
|
Injection
|
+
|
|
|
|
50% of costs of drugs for treatment at special class, class I hospitals and class II oncology hospitals shall be covered by the Health insurance fund;
|
|
|
|
393
|
Cetuximab
|
Infusion
|
+
|
|
|
|
Costs of drugs for treatment of RAS wild-type metastatic colorectal cancer and Head and neck squamous cell carcinoma (HNSCC) shall be covered by the Health insurance fund; 50% of costs of drugs for treatment at special class, class I hospitals and class II oncology hospitals shall be covered by the Health insurance fund;
|
|
|
|
394
|
Erlotinib
|
Oral administration
|
+
|
+
|
|
|
50% of costs of drugs for treatment of EGFR-positive non-small cell lung cancer shall be covered by the Health insurance fund.
|
|
|
|
395
|
Gefitinib
|
Oral administration
|
+
|
+
|
|
|
50% of costs of drugs for treatment of EGFR-positive non-small cell lung cancer shall be covered by the Health insurance fund.
|
|
|
|
396
|
Imatinib
|
Oral administration
|
+
|
|
|
|
80% of costs of drugs for treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumor (GIST) shall be covered by the Health insurance fund;
|
|
|
|
397
|
Nilotinib
|
Oral administration
|
+
|
|
|
|
80% of costs of drugs for treatment of chronic myeloid leukemia (CML) in patients intolerant of or resistant to Imatinib shall be covered by the Health insurance fund.
|
|
|
|
398
|
Nimotuzumab
|
Injection
|
+
|
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
399
|
Pazopanib
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
400
|
Rituximab
|
Injection
|
+
|
+
|
|
|
Costs of drugs for treatment of CD20-positive B-cell non-Hodgkin lymphoma shall be covered by the Health insurance fund
|
|
|
|
401
|
Sorafenib
|
Oral administration
|
+
|
+
|
|
|
50% of costs of drugs for treatment of hepatocellular carcinoma, locally advanced or metastatic differentiated thyroid cancer with failed Radioiodine therapy shall be covered by the Health insurance fund; 30% of costs of drugs for treatment of progressive renal cell carcinoma.
|
|
|
|
402
|
Trastuzumab
|
Injection
|
+
|
|
|
|
Costs of drugs for treatment at special class, class I hospitals and class II oncology hospitals shall be covered by the Health insurance fund as follows: 60% of costs of drugs for HER2-positive breast cancer; 50% of costs of drugs for advanced or metastatic HER-2 positive gastric cancer.
|
|
|
|
|
83. Drugs for endocrine treatment
|
|
|
|
403
|
Abiraterone acetate
|
Oral administration
|
+
|
+
|
|
|
30% of costs of drugs for treatment of prostate cancer after failed endocrine (hormone) therapy or failed chemotherapy treatment shall be covered by the Health insurance fund.
|
|
|
|
404
|
Anastrozole
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
405
|
Bicalutamide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
406
|
Degarelix
|
Injection
|
+
|
+
|
|
|
|
|
|
|
407
|
Exemestan
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
408
|
Flutamide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
409
|
Fulvestrant
|
Injection
|
+
|
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
410
|
Goserelin acetate
|
Injection
|
+
|
+
|
|
|
|
|
|
|
411
|
Letrozole
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
412
|
Leuprorelin acetate
|
Injection
|
+
|
+
|
|
|
|
|
|
|
413
|
Tamoxifen
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
414
|
Triptorelin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
|
8.4. Immunosuppressive drugs
|
|
|
|
415
|
Anti-thymocyte globulin
|
Injection
|
+
|
|
|
|
|
|
|
|
416
|
Azathioprine
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
417
|
Human interferon antibodies
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for children aged under 6 with acute upper respiratory infections undergoing inpatient treatment shall be covered by the Health insurance fund.
|
|
|
|
418
|
Ciclosporin
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
419
|
Basiliximab
|
Injection
|
+
|
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
420
|
Glycyl funtumin (hydrochloride)
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of cancer undergoing adjuvant therapy shall be covered by the Health insurance fund.
|
|
|
|
421
|
Lenalidomide
|
Oral administration
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
422
|
Mycophenolate
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
423
|
Tacrolimus
|
Injection, Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment shall be covered by the Health insurance fund according to indications of one of the following cases:
- The package insert enclosed with the marketing authorization application which has been granted;
- Guidelines for diagnosis and treatment of hematology and organ transplantation of the Ministry of Health;
- For patients: heart transplant, lung transplant, pancreas transplant, limb transplant, intestine transplant; Lupus nephritis in adults or children who are inadequately responsive or resistant to corticosteroids; nephrotic syndrome in adults or children who are inadequately responsive or resistant to corticosteroids or are intolerant to corticosteroids.
|
|
|
|
424
|
Thalidomide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
|
8.5. Other drugs
|
|
|
|
425
|
Clodronate disodium
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
426
|
Pamidronate
|
Injection, Oral administration
|
+
|
+
|
|
|
|
|
|
|
|
9. DRUGS FOR TREATMENT OF UROLOGICAL DISORDERS
|
|
|
|
427
|
Alfuzosin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
428
|
Dutasteride
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
429
|
Flavoxate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
430
|
Lipidosterol serenoarepense (Lipid-sterol of Sercnoa repens)
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
431
|
Pinene + camphene + cineol + fenchone + borneol + anethol
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment after lithotripsy; or treatment of ureteral stones less than 7mm in size shall be covered by the Health insurance fund
|
|
|
|
432
|
Solifenacin succinate
|
Oral administration
|
+
|
+
|
|
|
70% of costs of drugs shall be covered by the Health insurance fund.
|
|
|
|
433
|
Tamsulosin hydrochloride
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
10. ANTIPARKINSONISM DRUGS
|
|
|
|
434
|
Levodopa + carbidopa
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
435
|
Levodopa + carbidopa monohydrate + entacapone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
436
|
Levodopa + benserazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
437
|
Piribedil
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
438
|
Pramipexol
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
439
|
Tolcapon
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
440
|
Rotigotine
|
Transdermal patch
|
+
|
|
|
|
50% of costs of drugs shall be covered by the Health insurance fund.
|
|
|
|
441
|
Trihexyphenidyl hydrochloride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
11. BLOOD-AFFECTING DRUGS
|
|
|
|
|
11.1. Antianaemia drugs
|
|
|
|
442
|
Folic acid (vitamin B9)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
443
|
Iron fumarate
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
444
|
Iron (III) hydroxide polymaltose
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
445
|
Iron protein succinylate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
446
|
Iron sucrose (or dextran)
|
Injection
|
+
|
+
|
|
|
|
|
|
|
447
|
Iron sulfate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
448
|
Iron ascorbate + folic acid
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
449
|
Iron fumarate + folic acid
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
450
|
Iron (III) hydroxide polymaltose + folic acid
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
451
|
Iron sulfate + folic acid
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
11.2. Drugs affecting coagulation
|
|
|
|
452
|
Carbazochrome
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
453
|
Cilostazol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
454
|
Enoxaparin (sodium)
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
455
|
Etamsylate
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
456
|
Heparin (sodium)
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
457
|
Nadroparin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
458
|
Phytomenadion (vitamin K1)
|
Injection, Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
459
|
Protamine sulfate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
460
|
Tranexamic acid
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
461
|
Triflusal
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
462
|
Warfarin (Sodium salt)
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
11.3. Blood and blood products
|
|
|
|
463
|
Albumin
|
Infusion
|
+
|
+
|
+
|
|
70% of costs of drugs shall be covered by the Health insurance fund in case of blood albumin levels ≤ 2.5 grams per deciliter or shock or progressive respiratory distress syndrome;
|
|
|
|
464
|
Albumin + immunoglobulin
|
Infusion
|
+
|
+
|
|
|
Costs of drugs for treatment of shock due to burns, trauma, dehydration, severe infections shall be covered by the Health insurance fund.
|
|
|
|
465
|
Plasma
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
466
|
Leukocyte
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
467
|
Erythrocyte
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
468
|
Platelet
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
469
|
Whole blood
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
470
|
Factor Eight Inhibitor Bypassing Activity - FEIBA
|
Injection
|
+
|
|
|
|
Costs of drugs for treatment of the following cases shall be covered by the Health insurance fund:
- Treatment of bleeding in hemophilia A patients with factor VIII inhibitors;
- Treatment of bleeding in hemophilia B patients with factor IX inhibitors;
- Treatment of bleeding in other patients (other than those with hemophilia) with acquired factor VIII inhibitors or acquired factor IX inhibitors;
- Treatment of surgical bleeding in patients with inhibitors requiring surgery.
|
|
|
|
471
|
Factor VIIa
|
Injection
|
+
|
+
|
|
|
|
|
|
|
472
|
Factor VIII
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
473
|
Factor IX
|
Infusion
|
+
|
+
|
|
|
|
|
|
|
474
|
Factor VIII + von Willebrand factor
|
Infusion
|
+
|
+
|
|
|
|
|
|
|
|
11.4. Macromolecular solutions
|
|
|
|
475
|
Dextran 40
|
Infusion
|
+
|
+
|
+
|
+
|
|
|
|
|
476
|
Dextran 60
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
477
|
Dextran 70
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
478
|
Gelatin
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
479
|
Gelatin succinyl + sodium chloride +sodium hydroxide
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
480
|
Hydroxyethyl starch
|
Infusion
|
+
|
+
|
+
|
|
Costs of drugs for treatment of hypovolemia due to acute blood loss when infusions alone do not improve clinically; treatment of severe dengue hemorrhagic fever shall be covered by the Health insurance fund according to the Guidelines for diagnosis and treatment of dengue hemorrhagic fever of the Ministry of Health.
|
|
|
|
|
11.5. Other drugs
|
|
|
|
481
|
Deferasirox
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
482
|
Deferipron
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
483
|
Eltrombopag
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of chronic immune thrombocytopenic hemorrhage in adults refractory to splenectomy.
|
|
|
|
484
|
Erythropoietin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
485
|
Filgrastim
|
Injection
|
+
|
+
|
|
|
|
|
|
|
486
|
Methoxy polyethylene glycol epoetin beta
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
487
|
Pegfilgrastim
|
Injection
|
+
|
+
|
|
|
|
|
|
|
|
12. Cardiovascular drugs
|
|
|
|
|
12.1. Antianginal drugs
|
|
|
|
488
|
Diltiazem
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
489
|
Glyceryl trinitrate (Nitroglycerin)
|
Injection, nebulizer, transdermal patch
|
+
|
+
|
+
|
|
|
|
|
|
sublingual administration
|
+
|
+
|
+
|
+
|
|
|
|
|
490
|
Isosorbid (dinitrate or mononitrate)
|
Injection, Nebules, aerosol spray
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, sublingual administration
|
+
|
+
|
+
|
+
|
|
|
|
|
491
|
Nicorandil
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
492
|
Trimetazidin
|
Oral administration
|
+
|
+
|
+
|
+
|
Costs of drugs for symptomatic treatment in patients with stable angina who are not adequately controlled or patients who are intolerant to other therapies shall be covered by the Health insurance fund.
|
|
|
|
|
12.2. Antiarrhythmic drugs
|
|
|
|
493
|
Adenosine triphosphate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
494
|
Amiodarone hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
495
|
Isoprenaline
|
Injection, Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for emergency treatment of cardiovascular collapse, heart block, bronchospasm during anesthesia shall be covered by the Health insurance fund.
|
|
|
|
496
|
Propranolol hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
497
|
Sotalol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
498
|
Verapamil hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
12.3. Antihypertensive drugs
|
|
|
|
499
|
Acebutolol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
500
|
Amlodipine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
501
|
Amlodipine + atorvastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
502
|
Amlodipine + losartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
503
|
Amlodipine + lisinopril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
504
|
Amlodipin + indapamide
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis and treatment of the Ministry of Health.
|
|
|
|
505
|
Amlodipine + indapamide + perindopril
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis and treatment of the Ministry of Health.
|
|
|
|
506
|
Amlodipine + telmisartan
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis and treatment of the Ministry of Health.
|
|
|
|
507
|
Amlodipine + valsartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
508
|
Amlodipine + valsartan + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines for diagnosis and treatment of the Ministry of Health.
|
|
|
|
509
|
Atenolol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
510
|
Benazepril hydrochloride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
511
|
Bisoprolol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
512
|
Bisoprolol + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
513
|
Candesartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
514
|
Candesartan + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
515
|
Captopril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
516
|
Captopril + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
517
|
Carvedilol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
518
|
Cilnidipine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
519
|
Clonidine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
520
|
Doxazosin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
521
|
Enalapril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
522
|
Enalapril + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
523
|
Felodipine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
524
|
Felodipine + metoprolol tartrate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
525
|
Hydralazine
|
Infusion
|
+
|
+
|
|
|
|
|
|
|
526
|
Imidapril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
527
|
Indapamide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
528
|
Irbesartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
529
|
Irbesartan + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
530
|
Lacidipine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
531
|
Lercanidipine hydrochloride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
532
|
Lisinopril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
533
|
Lisinopril + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
534
|
Losartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
535
|
Losartan + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
536
|
Methyldopa
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
537
|
Metoprolol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
538
|
Nebivolol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
539
|
Nicardipine
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
540
|
Nifedipine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
541
|
Perindopril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
542
|
Perindopril + amlodipine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
543
|
Perindopril + indapamide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
544
|
Quinapril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
545
|
Ramipril
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
546
|
Rilmenidine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
547
|
Telmisartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
548
|
Telmisartan + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
549
|
Valsartan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
550
|
Valsartan + hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
12.4. Antihypotensive drugs
|
|
|
|
551
|
Heptaminol hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
12.5. Drugs for treatment of heart failure
|
|
|
|
552
|
Carvedilol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
553
|
Digoxin
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Injection
|
+
|
+
|
+
|
+
|
For general clinics and commune health stations: Costs of drugs for emergency treatment shall be covered by the Health insurance fund.
|
|
|
|
554
|
Dobutamine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
555
|
Dopamine hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
556
|
Ivabradine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
557
|
Milrinon
|
Injection
|
+
|
+
|
|
|
|
|
|
|
|
12.6. Antithrombotic drugs
|
|
|
|
558
|
Acenocoumarol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
559
|
Acetylsalicylic acid (DL-lysine-acetylsalicylate)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
560
|
Acetylsalicylic acid + clopidogrel
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
561
|
Alteplase
|
Injection
|
+
|
+
|
|
|
|
|
|
|
562
|
Apixaban
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for COVID-19 treatments shall be covered according to guidlines on diagnosis and treatments for COVID-19 of the Ministry of Health.
|
|
|
|
563
|
Ciopidogrel
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
564
|
Dabigatran
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
565
|
Dipyridamol + acetylsalicylic acid
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
566
|
Eptifibatide
|
Injection
|
+
|
+
|
|
|
|
|
|
|
567
|
Fondaparinux sodium
|
Injection
|
+
|
|
|
|
|
|
|
|
568
|
Rivaroxaban
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
569
|
Streptokinase
|
Injection
|
+
|
+
|
|
|
Costs of Streptokinase shall be covered by the Health insurance fund if it is used for injection or used to irrigate the pleural cavity in cases of pleurisy or empyema.
|
|
|
|
570
|
Tenecteplase
|
Injection
|
+
|
+
|
|
|
|
|
|
|
571
|
Ticagrelor
|
Oral administration
|
+
|
+
|
|
|
70% of cost of this drug for treatment shall be covered by the Health insurance fund
|
|
|
|
572
|
Urokinase
|
Injection
|
+
|
+
|
+
|
|
Cost of Urokinase shall be covered by the Health insurance fund if it is used for injection or used to irrigate the pleural cavity in cases of pleurisy or empyema.
|
|
|
|
|
12.7. Hypolipidemic drugs
|
|
|
|
573
|
Atorvastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
For commune health stations, cost of this drug for treatment of lipid disorders shall be covered by the Health insurance fund according to guidelines on diagnosis and treatments of the Ministry of Health.
|
|
|
|
574
|
Atorvastatin + ezetimibe
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
575
|
Bezafibrate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
576
|
Ciprofibrate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
577
|
Ezetimibe
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
578
|
Fenofibrate
|
Oral administration
|
+
|
+
|
+
|
|
For commune health stations, cost of this drug for treatment of lipid disorders shall be covered by the Health insurance fund according to guidelines on diagnosis of the Ministry of Health.
|
|
|
|
579
|
Fluvastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
580
|
Gemfibrozil
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
581
|
Lovastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
582
|
Pravastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
583
|
Rosuvastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
584
|
Simvastatin
|
Oral administration
|
+
|
+
|
+
|
+
|
For commune health stations, cost of this drug for treatment of lipid disorders shall be covered by the Health insurance fund according to guidelines on diagnosis and treatments of the Ministry of Health.
|
|
|
|
585
|
Simvastatin + ezetimibe
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
12.8. Other drugs
|
|
|
|
586
|
Bosentan
|
Oral administration
|
+
|
|
|
|
50% of costs of drugs for treatment of pulmonary hypertension shall be covered by the Health insurance fund;
|
|
|
|
587
|
Iloprost
|
Injection, inhalation, Eye drops
|
+
|
+
|
|
|
|
|
|
|
588
|
Prostaglandin E1
|
Injection
|
+
|
|
|
|
Costs of drugs for emergency treatment of patent ductus arteriosus (PDA) for newborns with congenital heart defects requiring maintenance of ductus arteriosus.
|
|
|
|
589
|
Fructose 1,6 diphosphate
|
Injection
|
+
|
+
|
|
|
Costs of drugs for treatment shall be covered by the Health insurance fund in the following cases:
- Myocardial ischemia, early-onset myocardial infarction, cardiac surgery with extracorporeal circulation;
- Shock caused by cardiac arrest, trauma, bleeding, stroke or severe infection;
- After liver surgery or severe burns.
|
|
|
|
590
|
Indomethacin
|
Injection
|
+
|
|
|
|
Costs of drugs for treatment of patent ductus arteriosus in premature infants shall be covered by the Health insurance fund.
|
|
|
|
591
|
Magnesium chloride + potassium chloride + procaine hydrochloride
|
Injection
|
+
|
|
|
|
|
|
|
|
592
|
Naftidrofuryl
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
593
|
Nimodipine
|
Injection, Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of subarachnoid hemorrhage (SHA) caused by brain aneurysm or trauma shall be covered by the Health insurance fund.
|
|
|
|
594
|
Nitrogen monoxide (NO)
|
Compressed air
|
+
|
|
|
|
Costs of drugs used for treatment of pulmonary hypertension in children; or used during and after cardiovascular surgery and intervention shall be covered by the Health insurance fund.
|
|
|
|
595
|
Succinic acid + nicotinamide + inosine + riboflavin sodium phosphate
|
Injection
|
+
|
+
|
|
|
Costs of drugs for treatment of acute ischemic stroke shall be covered by the Health insurance fund.
|
|
|
|
596
|
Sulbutiamine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
597
|
Tolazoline
|
Injection, Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
13. DERMATOLOGICAL DRUGS
|
|
|
|
598
|
Acitretin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
599
|
Adapalene
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
600
|
Alpha - terpineol
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
601
|
Amorolfine
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
602
|
Azelaic acid
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
603
|
Benzoic acid + salicylic acid
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
604
|
Benzoyl peroxide
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
605
|
Talcum powder
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
606
|
Calcipotriol
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
607
|
Calcipotriol + betamethasone dipropionate
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
608
|
Capsaicin
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
609
|
Clotrimazole
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
610
|
Clobetasol propionate
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
611
|
Clobetasol butyrate
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
612
|
Cortisone
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
613
|
Alcohol A.S.A
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
614
|
Boric alcohol
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
615
|
BSI alcohol
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
616
|
Crotamiton
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
617
|
Dapsone
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
618
|
Desonide
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
619
|
Dexpanthenol (panthenol, vitamin B5)
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
620
|
Diethylphtalate
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
621
|
S-bioallethrin + piperonyl butoxide
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
622
|
Flumethasone + clioquinol
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
623
|
Fusidic acid
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
624
|
Fusidic acid + betamethasone
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
625
|
Fusidic acid + hydrocortisone
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
626
|
Isotretinoin
|
Oral administration, topical administration
|
+
|
+
|
+
|
|
|
|
|
|
627
|
Zinc oxide
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
628
|
Mometasone furoate
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
629
|
Mometasone furoate + salicylic acid
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
630
|
Mupirocin
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
631
|
Sodium hydrocarbonate
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
632
|
Nepidermin
|
Topical spray
|
+
|
+
|
|
|
|
|
|
|
633
|
Hydrogen peroxide
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
634
|
Para aminobenzoic acid
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
635
|
Recombinant human
Epidermal Growth Factor (rhEGF)
|
Injection
|
+
|
|
|
|
Costs of drugs for treatment of severe ulcers due to grade 3 or 4 diabetes shall be covered by the Health insurance fund.
|
|
|
|
636
|
Salicylic acid
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
637
|
Salicylic acid + betamethasone dipropionate
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
638
|
Secukinumab
|
Injection
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
639
|
Tacrolimus
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
640
|
Tretinoin
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
641
|
Trolamin
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
642
|
Tyrothricin
|
Topical administration
|
+
|
+
|
|
|
|
|
|
|
643
|
Urea
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
644
|
Ustekinumab
|
Injection
|
+
|
+
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
|
14. DIAGNOSTIC AGENTS
|
|
|
|
|
14.1. Ophthalmic drugs
|
|
|
|
645
|
Fluorescein (sodium)
|
Injection, Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
|
14.2. Radiocontrast media
|
|
|
|
646
|
Adipiodon (meglumin)
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
647
|
Amidotrizoate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
648
|
Barium sulfate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
649
|
ethyl esters of iodinated fatty acids of poppy seed oil, EEIFAPSO
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
650
|
Gadobenic acid (dimeglumin)
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of intravenous injection during liver imaging shall be covered by the Health insurance fund.
|
|
|
|
651
|
Gadobutrol
|
Injection
|
+
|
|
|
|
|
|
|
|
652
|
Gadoteric acid
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
653
|
lobitridol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
654
|
Iodixanol
|
Injection
|
+
|
|
|
|
50% of costs shall be covered by the Health insurance fund
|
|
|
|
655
|
Iohexol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
656
|
lopamidol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
657
|
Iopromide acid
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
658
|
Sodium ioxitalamate + meglumin ioxitalamate
|
Injection
|
+
|
+
|
|
|
|
|
|
|
659
|
Sodium and meglumin salts of ioxaglic acid
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
|
143. Other drugs
|
|
|
|
660
|
Polidocanol
|
Injection
|
+
|
+
|
|
|
|
|
|
|
|
15. DISINFECTANTS AND ANTISEPTICS
|
|
|
|
661
|
70° alcohol
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
662
|
Iodine alcohol
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
663
|
Copper sulfate
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
664
|
Povidon iodide
|
Topical administration, vaginal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
665
|
Concentrated sodium hypochloride
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
666
|
Sodium chloride
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
16. DIURETICS
|
|
|
|
667
|
Furosemide
|
Injection
|
+
|
+
|
+
|
+
|
For general clinics and commune health stations: Costs of drugs for emergency treatment shall be covered by the Health insurance fund.
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
668
|
Furosemide + spironolactone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
669
|
Hydrochlorothiazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
670
|
Spironolactone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
17. GASTROINTESTINAL DRUGS
|
|
|
|
|
17.1. Antacids and other antiulcer drugs affecting the gastrointestinal tract
|
|
|
|
671
|
Aluminum phosphate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
672
|
Activated attapulgite mormoiron + mixture of magnesium carbonate-aluminum hydroxide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
673
|
Bismuth
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
674
|
Cimetidine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
675
|
Famotidine
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
676
|
Guaiazulene + dimethicone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
677
|
Lansoprazole
|
Oral administration
|
+
|
+
|
+
|
|
Heath insurance shall cover drugs used under indications of the package insert enclosed with the marketing authorization application which has been granted, or under diagnosis and treatment instructions of BYT, or under indications for prevention of gastrointestinal ulcer or herrmorage due to stress in ICU patients.
|
|
|
|
678
|
Magnesium hydroxide + aluminum hydroxide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
679
|
Magnesium hydroxide + aluminum hydroxide + simethicone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
680
|
Magnesium trisilicate + aluminum hydroxide
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
681
|
Nizatidine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
682
|
Omeprazole
|
Injection
|
+
|
+
|
+
|
|
Heath insurance shall cover drugs used under indications of the package insert enclosed with the marketing authorization application which has been granted, or under diagnosis and treatment instructions of BYT, or under indications for prevention of gastrointestinal ulcer or herrmorage due to stress in ICU patients
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
683
|
Esomeprazole
|
Injection
|
+
|
+
|
+
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
684
|
Pantoprazole
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
685
|
Rabeprazole
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
|
|
|
|
|
686
|
Ranitidine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
687
|
Ranitidine + bismuth + sucralfate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
688
|
Rebamipide
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
689
|
Sucralfate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
17.2. Antiemetics
|
|
|
|
690
|
Dimenhydrinate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
691
|
Domperidone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
692
|
Granisetron hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
693
|
Metoclopramide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, rectal suppositories
|
+
|
+
|
+
|
+
|
|
|
|
|
694
|
Ondansetron
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
695
|
Palonosetron hydrochloride
|
Injection
|
+
|
+
|
|
|
|
|
|
|
|
17.3. Antispasmodic drugs
|
|
|
|
696
|
Alverin citrate
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
697
|
Alverin citrate + simethicone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
698
|
Atropin sulfate
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
699
|
Drotaverine hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
700
|
Hyoscine butylbromide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
701
|
Mebeverine hydrochloride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
702
|
Papaverine hydrochloride
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
703
|
Phloroglucinol hydrate + trimethyl phloroglucinol
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
704
|
Tiemonium methylsulfate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
705
|
Tiropramide hydrochloride
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
17.4. Laxatives
|
|
|
|
706
|
Bisacodyl
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
707
|
Docusate sodium
|
Oral administration, anal/rectal enema
|
+
|
+
|
+
|
+
|
|
|
|
|
708
|
Glycerol
|
Anal/rectal enema
|
+
|
+
|
+
|
+
|
|
|
|
|
709
|
Lactulose
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
710
|
Macrogol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
711
|
Macrogol + Sodium sulfate + Sodium bicarbonate + Sodium chloride + Potassium chloride
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
712
|
Magnesium sulfate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
713
|
Monobasic sodium phosphate + sodium phosphate dibasic
|
Oral administration, anal/rectal enema, Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
714
|
Sorbitol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
715
|
Sorbitol + Sodium citrate
|
Anal/rectal enema
|
+
|
+
|
+
|
|
|
|
|
|
|
17.5. Drug for treatment of diarrhoea
|
|
|
|
716
|
Activated attapulgite mormoiron
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
717
|
Bacillus subtilis
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
718
|
Bacillus clausii
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
719
|
Berberine (hydrochloride)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
720
|
Dioctahedral smectite
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
721
|
Diosmectite
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
722
|
Gelatin tannate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
723
|
Zinc sulfate
|
Oral administration, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
724
|
Zinc gluconate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
725
|
Lactobacillus acidophilus
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
726
|
Loperamide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
727
|
Nifuroxazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
728
|
Racecadotril
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
729
|
Saccharomyces boulardii
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
17.6. Drugs for treatment of haemorrhoids
|
|
|
|
730
|
Ginkgo biloba glue + heptaminol chlohydrate + troxerutin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
731
|
Diosmin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
732
|
Diosmin + hesperidin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
17.7. Other drugs
|
|
|
|
733
|
Amylase + lipase + protease
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
734
|
Citrulline malate
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
735
|
Itopride
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
736
|
L-Omithine - L- aspartate
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of L-Omithine - L- aspartate shall be covered by the Health insurance fund.
|
|
|
|
737
|
Mesalazine (mesalamin)
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Rectal enema, rectal suppositories
|
+
|
|
|
|
|
|
|
|
738
|
Octreotide
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
739
|
Simethicone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
740
|
Silymarin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
741
|
Somatostatin
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
742
|
Terlipressin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
743
|
Trimebutine maleate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
744
|
Ursodeoxycholic acid
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
745
|
Otilonium bromide
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
18. HORMONES AND ENDOCRINE MEDICINES
|
|
|
|
|
18.1. Adrenal hormones and synthetic substitutes
|
|
|
|
746
|
Beclometasone (dipropionate)
|
Nasal spray, throat spray
|
+
|
+
|
+
|
|
|
|
|
|
747
|
Betamethasone
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Eye drops, ear drops, nasal drops, topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
748
|
Danazole
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
749
|
Dexamethasone
|
Injection
|
+
|
+
|
+
|
|
Cost of this drug shall not be covered by the Health insurance fund in case this drug is used in intravitreal injection, intraocular injection.
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
750
|
Dexamethasone phosphate + neomycin
|
Eye drops, nasal drops
|
+
|
+
|
+
|
+
|
|
|
|
|
751
|
Betamethasone + dexchlorpheniramine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
752
|
Fludrocortisone acetate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
753
|
Fluocinolone acetonide
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
754
|
Hydrocortisone
|
Injection, oral administration, ophthalmic administration
|
+
|
+
|
+
|
|
|
|
|
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
755
|
Methylprednisolone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
+
|
For general clinics and commune health stations: Costs of drugs for Anaphylactic emergency treatment shall be covered by the Health insurance fund.
|
|
|
|
756
|
Prednisolone acetate (sodium phosphate)
|
Injection, eye drops
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
757
|
Prednisone
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
758
|
Triamcinolone acetonide
|
Injection, topical administration
|
+
|
+
|
+
|
|
|
|
|
|
759
|
Triamcinolone
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
760
|
Triamcinolone + econazole
|
Topical administration
|
+
|
+
|
+
|
|
|
|
|
|
761
|
Cyproterone acetate
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
762
|
Somatropin
|
Injection
|
+
|
+
|
|
|
Costs of this drug for treatment of growth hormone deficiency causing small-for-gestational-age (SGA) newborns, Turner syndrome, growth retardation due to chronic renal failure, and Prader-Willi syndrome shall be covered by the Health insurance fund as follows: 70% of costs for children aged under 16; 50% of costs for the other ages.
|
|
|
|
|
18.2. Androgen, estrogen, and progesteron products
|
|
|
|
763
|
Dydrogesterone
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
764
|
Estradiol valerate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Injection
|
+
|
+
|
|
|
|
|
|
|
765
|
Estriol
|
Oral administration, vaginal suppositories
|
+
|
+
|
+
|
|
|
|
|
|
766
|
Estrogen + norgestrel
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
767
|
Ethinyl estradiol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
768
|
Ethinyl estradiol + cyproterone acetate
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
769
|
Lynestrenol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
770
|
Nandrolone decanoate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
771
|
Norethisterone
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
772
|
Nomegestrol acetate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
773
|
Promestriene
|
Topical administration, vaginal suppositories
|
+
|
+
|
+
|
|
|
|
|
|
774
|
Progesterone
|
Injection, Oral administration, Topical administration, vaginal suppositories
|
+
|
+
|
+
|
|
|
|
|
|
775
|
Raloxifene
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
776
|
Testosterone (acetate, propionate, undecanoate)
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
18.3. Insulins and antidiabetic medicines
|
|
|
|
777
|
Acarbose
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
778
|
Dapagliflozin
|
Oral administration
|
+
|
+
|
|
|
70% of cost of this drug for treatment shall be covered by the Health insurance fund
|
|
|
|
779
|
Empagliflozin
|
Oral administration
|
+
|
+
|
|
|
70% of cost of this drug for treatment shall be covered by the Health insurance fund
|
|
|
|
780
|
Glibenclamide + metformin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
781
|
Gliclazide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
782
|
Gliclazide + metformin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
783
|
Glimepiride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
784
|
Glimepiride + metformin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
785
|
Glipizide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
786
|
Short-acting, rapid-acting insulin analogs
(Aspart, Lispro, Glulisine)
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines on diagnosis, treatment and management of diabetes of the Ministry of Health.
|
|
|
|
787
|
Long-acting, slow-acting insulin analogs (Glargine, Detemir, Degludec)
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines on diagnosis, treatment and management of diabetes of the Ministry of Health.
|
|
|
|
788
|
Mixed insulin analogs
|
Injection
|
+
|
+
|
+
|
|
Costs of mixed insulin analogs shall be covered by the Health insurance fund as follows: 50% of costs if they are mixed between insulin Degludec và insulin Aspart, 100% of costs if they are mixed between the others.
Drugs are dispensed at commune health stations according to the guidelines on diagnosis, treatment and management of diabetes of the Ministry of Health.
|
|
|
|
789
|
Short-acting, fast-acting human insulin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines on diagnosis, treatment and management of diabetes of the Ministry of Health.
|
|
|
|
790
|
Intermediate-acting human insulin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines on diagnosis, treatment and management of diabetes of the Ministry of Health.
|
|
|
|
791
|
Mixed human insulin
|
Injection
|
+
|
+
|
+
|
|
Drugs are dispensed at commune health stations according to the guidelines on diagnosis, treatment and management of diabetes of the Ministry of Health.
|
|
|
|
792
|
Linagliptin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
793
|
Linagliptin + metformin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
794
|
Liraglutide
|
Injection
|
+
|
|
|
|
30% of costs of drugs for treatment of type 2 diabetes shall be covered by the Health insurance fund if patients simultaneously meet the following criteria:
- Over 40 years old, BMI > 23, type 2 diabetes, cardiovascular disease or hypertension;
- Uncontrolled blood sugar (HbA1C>9) after 3 months;
- Renal failure with CrCl concentration <59 ml/min.
|
|
|
|
795
|
Metformin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
796
|
Repaglinide
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
797
|
Saxagliptin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
798
|
Saxagliptin + metformin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
799
|
Sitagliptin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
800
|
Sitagliptin + metformin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
801
|
Vildagliptin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
802
|
Vildagliptin + metformin
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
|
18.4. Thyroid hormone, parathyroid hormone, and synthetic antithyroid drugs
|
|
|
|
803
|
Carbimazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
804
|
Levothyroxine (Sodium salt)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
805
|
Propylthiouracil (PTU)
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
806
|
Thiamazole
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
18.5. Drugs for treatment of diabetes insipidus
|
|
|
|
807
|
Desmopressin
|
Injection, oral administration, nasal spray
|
+
|
+
|
|
|
|
|
|
|
808
|
Vasopressin
|
Injection, oral administration
|
+
|
+
|
|
|
|
|
|
|
|
18.6. Other drugs
|
|
|
|
809
|
Alglucosidase alfa
|
Infusion
|
+
|
|
|
|
30% of cost of this drug for treatment shall be covered by the Health insurance fund
|
|
|
|
|
19. SERA AND IMMUNOGLOBULINS
|
|
|
|
810
|
Immune globulin
|
Injection
|
+
|
+
|
|
|
Costs of drugs for treatment of autoimmune thrombocytopenic purpura unresponsive to corticosteroids, Guillain Barre syndrome, Kawasaki disease; treatment of severe infections with reduced IgG; alternative treatment for patients with IgG deficiency; treatment of hand-foot-mouth disease; Measles exposure treatment, measles treatment when there is severe infection or rapidly progressing respiratory failure or encephalitis according to the Ministry of Health's guidelines on measles diagnosis and treatment; treatment of Multisystem Inflammatory Syndrome associated with COVID-19 in children (MIS-C) according to the Ministry of Health's guidelines on diagnosis and treatment of COVID-19 in children; treatment of thrombosis and thrombocytopenia syndrome after COVID-19 vaccination according to the Ministry of Health's guidelines on diagnosis and treatment of thrombocytopenia and thrombosis after COVID-19 vaccination shall be covered by the Health insurance fund.
|
|
|
|
811
|
Anti-diphtheria serum
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
812
|
Antirabies serum
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
813
|
Antivenom serum
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
814
|
Anti-tetanus serum
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
|
20. MUSCLE SOFTENERS AND CHOLINESTERASE INHIBITORS
|
|
|
|
815
|
Baclofen
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
816
|
Botulinum toxin
|
Injection
|
+
|
+
|
|
|
|
|
|
|
817
|
Eperisone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
818
|
Mephenesin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
819
|
Pyridostigmine bromide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
820
|
Rivastigmine
|
Oral administration, Transdermal patch
|
+
|
+
|
|
|
|
|
|
|
821
|
Tizanidine hydrochloride
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
822
|
Thiocolchicoside
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
823
|
Tolperisone
|
Oral administration
|
+
|
+
|
+
|
+
|
Costs of drugs for treatment of muscle spasticity after stroke shall be covered by the Health insurance fund.
|
|
|
|
|
21. OPHTHALMOLOGICAL DRUGS AND OTORHINOLARYNGOLOGICAL DRUGS
|
|
|
|
|
21.1. Ophthalmological drugs
|
|
|
|
824
|
Acetazolamide
|
Injection
|
+
|
+
|
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
825
|
Atropin sulfate
|
Eye drops
|
+
|
+
|
+
|
+
|
|
|
|
|
826
|
Besifloxacin
|
Eye drops
|
+
|
|
|
|
Costs of drugs used for treatment of infections caused by Staphylococcus aureus in cases of resistance to other antibiotics and used for treatment at special class, class I hospitals and class II eye hospitals shall be covered by the Health insurance fund.
|
|
|
|
827
|
Betaxolol
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
828
|
Bimatoprost
|
Eye drops
|
+
|
+
|
|
|
Costs of drugs used for treatment at special class, class I, II hospitals and class III oncology hospitals shall be covered by the Health insurance fund.
|
|
|
|
829
|
Bimatoprost + timolol
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
830
|
Brimonidine tartrate
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
831
|
Brimonidine tartrate + timolol
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
832
|
Brinzolamide
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
833
|
Brinzolamide + timolol
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
834
|
Bromfenac
|
Eye drops
|
+
|
+
|
|
|
Costs of drugs used for treatment of inflammation after cataract surgery; used for treatment at special class, class I, II hospitals and class III eye hospitals shall be covered by the Health insurance fund.
|
|
|
|
835
|
Carbomer
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
836
|
Cyclosporine
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
837
|
Dexamethasone + framycetin
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
838
|
Dexpanthenol
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
839
|
Dinatri inosine monophosphate
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
840
|
Fluorometholone
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
841
|
Glycerine
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
842
|
Hexamidine di-isetionate
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
843
|
Hyaluronidase
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
844
|
Hydroxypropylmethylcellulose
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
845
|
Indomethacin
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
846
|
Potassium iodide + Potassium iodide
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
847
|
Latanoprost
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
848
|
Latanoprost + Timolol maleate
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
849
|
Loteprednol etabonate
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
850
|
Moxifloxacin + dexamethasone
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
851
|
Natamycin
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
852
|
Sodium carboxymethylcellulose (sodium CMC)
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
853
|
Sodium carboxymethylcellulose + glycerin
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
854
|
Sodium chloride
|
Eye drops, nasal drops
|
+
|
+
|
+
|
+
|
|
|
|
|
855
|
Sodium diquafosol
|
Eye drops
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, class II hospitals and class III eye hospitals shall be covered by the Health insurance fund.
|
|
|
|
856
|
Sodium hyaluronate
|
Injection, Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
857
|
Nepafenac
|
Eye drops
|
+
|
+
|
|
|
Costs of drugs used for treatment of inflammation after cataract surgery in patients with diabetes mellitus; used for treatment at special class, class I, class II hospitals and class III eye hospitals shall be covered by the Health insurance fund.
|
|
|
|
858
|
Olopatadine hydrochloride
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
859
|
Pemirolast potassium
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
860
|
Pilocarpine
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
861
|
Pirenoxin
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
862
|
Polyethylene glycol + propylene glycol
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
863
|
Ranibizumab
|
Intravitreal injection
|
+
|
|
|
|
Costs of drugs used for treatment in ophthalmology departments of special class hospitals; class I, II eye hospitals; Huu Nghi hospital, Thong Nhat hospital, Da Nang C hospital shall be covered by the Health insurance fund for beneficiaries according to Guidance No. 52-HD/BTCTW dated December 02, 12, 2005 of the Organization Commission of the Central Committee of Vietnam on registration of initial medical examination and treatment at hospitals.
|
|
|
|
864
|
Tafluprost
|
Eye drops
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, class II hospitals and class III eye hospitals shall be covered by the Health insurance fund.
|
|
|
|
865
|
Tetracaine
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
866
|
Tetryzoline
|
Eye drops, nasal drops
|
+
|
+
|
+
|
|
|
|
|
|
867
|
Timolol
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
868
|
Travoprost
|
Eye drops
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, class II hospitals and class III eye hospitals shall be covered by the Health insurance fund.
|
|
|
|
869
|
Travoprost + timolol
|
Eye drops
|
+
|
+
|
|
|
|
|
|
|
870
|
Tropicamide
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
871
|
Tropicamide + phenylephrine hydrochloride
|
Eye drops
|
+
|
+
|
+
|
|
|
|
|
|
|
21.2. Otorhinolaryngological drugs
|
|
|
|
872
|
Betahistine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
873
|
Boric alcohol
|
Topical administratiom
|
+
|
+
|
+
|
+
|
|
|
|
|
874
|
Fluticasone furoate
|
Nasal spray
|
+
|
+
|
+
|
|
|
|
|
|
875
|
Fluticasone propionate
|
Topical administration, Nebules, nasal spray, throat spray
|
+
|
+
|
+
|
|
|
|
|
|
876
|
Naphazoline
|
Nasal drops
|
+
|
+
|
+
|
+
|
|
|
|
|
877
|
Sodium borate
|
Ear drops
|
+
|
+
|
|
|
|
|
|
|
878
|
Phenazone + lidocaine hydrochloride
|
Ear drops
|
+
|
+
|
+
|
|
|
|
|
|
879
|
Rifamycin
|
Ear drops
|
+
|
+
|
|
|
|
|
|
|
880
|
Tixocortol pivalate
|
Topical administration, nebulizer
|
+
|
+
|
+
|
+
|
|
|
|
|
881
|
Triprolidine hydrochloride + pseudoephedrine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
882
|
Tyrothricin + benzocaine + benzalkonium
|
Sublingual, buccal and sublabial administration
|
+
|
+
|
|
|
|
|
|
|
883
|
Xylometazoline
|
Nasal drops, nebulizer
|
+
|
+
|
+
|
+
|
|
|
|
|
|
22. OXYTOCICS, POSTPARTUM HAEMOSTATICS AND ANTIOXYTOCICS
|
|
|
|
|
22.1 Oxytocics and postpartum haemostatics
|
|
|
|
884
|
Carbetocin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
885
|
Carboprost tromethamine
|
Injection
|
+
|
+
|
|
|
|
|
|
|
886
|
Dinoprostone
|
Vaginal suppositories
|
+
|
|
|
|
Costs of drugs for treatment at special class, class I hospitals and class II Obstetrics hospitals shall be covered by the Health insurance fund.
|
|
|
|
887
|
Levonorgestrel
|
Endocervical insertion
|
+
|
|
|
|
Costs of drugs for treatment of idiopathic menorrhagia shall be covered by the Health insurance fund.
|
|
|
|
888
|
Methyl ergometrine maleate
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
889
|
Oxytocin
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
890
|
Ergometrine (hydrogen maleate)
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
891
|
Misoprostol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Vaginal suppositories
|
+
|
+
|
|
|
|
|
|
|
|
22.2. Antioxytocics
|
|
|
|
892
|
Atosiban
|
Infusion
|
+
|
+
|
|
|
|
|
|
|
893
|
Papaverin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
894
|
Salbutamol sulfate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
|
23. HEMODIALYSIS AND PERITONEAL DIALYSIS SOLUTION
|
|
|
|
895
|
Intraperitoneal dialysis solution
|
Local (immersion into the peritoneal cavity)
|
+
|
+
|
+
|
|
|
|
|
|
896
|
Bicarbonate or acetate solutions for renal filtration
|
Dialysis solution
|
+
|
+
|
+
|
|
|
|
|
|
897
|
Continuous hemodialysis solution (with or without citrate anticoagulation; with or without lactate)
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
|
24. ANTIPSYCHOTIC DRUGS and drugs affecting nervous system
|
|
|
|
|
24.1. Sedative
|
|
|
|
898
|
Bromazepam
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
899
|
Chlorazepate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
900
|
Diazepam
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
Injection form: Regarding general clinics and commune health stations: Costs of drugs for emergency treatment shall be covered by the Health insurance fund.
|
|
|
|
901
|
Etifoxine hydrochloride
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
902
|
Hydroxyzine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
903
|
Lorazepam
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Injection
|
+
|
|
|
|
|
|
|
|
904
|
Rotundin
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
24.2. Sporofic drugs
|
|
|
|
905
|
Zolpidem
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
906
|
Zopiclon
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
|
24.3. Antipsychotic drugs
|
|
|
|
907
|
Thioctic acid (Meglumine thioctate)
|
Oral administration, injection
|
+
|
+
|
|
|
Costs of drugs for treatment of sensory disorders caused by diabetic polyneuropathy shall be covered by the Health insurance fund.
|
|
|
|
908
|
Alprazolam
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
909
|
Amisulprid
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
910
|
Chlorpromazine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
911
|
Clozapine
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
912
|
Clonazepam
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
913
|
Donepezil
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
914
|
Flupentixol
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
915
|
Fluphenazine decanoate
|
Injection
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
916
|
Haloperidol
|
Injection, solution
|
+
|
+
|
+
|
|
|
|
|
|
Injection, ointment
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
917
|
Levomepromazine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
918
|
Levosulpiride
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
919
|
Meclophenoxate
|
Oral administration, injection
|
+
|
+
|
+
|
|
|
|
|
|
920
|
Olanzapine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
921
|
Quetiapine
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
922
|
Risperidon
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
923
|
Sulpiride
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
924
|
Thioridazine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
925
|
Tofisopam
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
926
|
Ziprasidon
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
927
|
Zuclopenthixol
|
Injection, oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
|
24.4. Antidepressant drugs
|
|
|
|
928
|
Amitriptyline hydrochloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
929
|
Citalopram
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
930
|
Clomipramine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
931
|
Fluoxetine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
932
|
Fluvoxamine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
933
|
Methylphenidate hydrochloride
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs used for treatment for children aged under 16, drugs used for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
934
|
Mirtazapine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
935
|
Paroxetine
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for treatment at special class, class I, II hospitals and psychiatric hospitals shall be covered by the Health insurance fund.
|
|
|
|
936
|
Sertraline
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
937
|
Tianeptine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
938
|
Venlafaxine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
|
24.5 Drugs affecting nervous system
|
|
|
|
939
|
Acetyl leucine
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
940
|
Peptides (Cerebrolysin concentrate)
|
Injection
|
+
|
+
|
+
|
|
50% of costs of drugs for treatment shall be covered by the Health insurance fund in the following cases:
- Acute stroke;
- After traumatic brain injury;
- After surgery for traumatic brain injury;
- After cranial nerve surgery.
|
|
|
|
941
|
Choline alfoscerate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
942
|
Citicolin
|
Injection
|
+
|
+
|
+
|
|
|
|
|
943
|
Panax notoginseng saponins
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
944
|
Cytidine-5-monophosphat disodium + uridine
|
Injection, oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of peripheral neuropathy shall be covered by the Health insurance fund.
|
|
|
|
945
|
Galantamine
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of mild to moderate Alzheimer's disease shall be covered by the Health insurance fund.
|
|
|
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of the following diseases shall be covered by the Health insurance fund:
- Peripheral neuropathy related to movement disorders in inpatients;
- Motor paralysis after spinal cord disease;
- Loss of mobility after stroke, cerebral palsy in children;
- Paralysis of bowel and bladder after surgery;
- Detoxification of Atropine and Atropine analogues.
|
|
|
|
946
|
Ginkgo biloba
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of pain caused by arteritis (angina when walking); visual disturbances (diabetic retinopathy); ENT (dizziness, tinnitus, hearing loss), sensory neurocirculatory disorders due to ischemia; Raynaud's syndrome.
|
|
|
|
947
|
Mecobalamin
|
Injection, oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of megaloblastic anemia, peripheral neuropathy due to vitamin B12 deficiency shall be covered by the Health insurance fund.
|
|
|
|
948
|
Pentoxifyllin
|
Oral administration
|
+
|
+
|
+
|
|
Costs of drugs for treatment of peripheral vascular disease (PVD) shall be covered by the Health insurance fund:
|
|
|
|
Injection
|
+
|
+
|
|
|
|
|
|
949
|
Piracetam
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of cortical myoclonus shall be covered by the Health insurance fund:
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
950
|
Vinpocetin
|
Injection
|
+
|
+
|
+
|
|
Costs of drugs for treatment of neurological symptoms of vascular dementia shall be covered by the Health insurance fund.
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
25. DRUGS AFFECTING THE RESPIRATORY TRACT
|
|
|
|
|
25.1. Drugs for treatment of asthma and chronic obstructive pulmonary disease
|
|
|
|
951
|
Aminophylline
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
952
|
Bambuterol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
953
|
Budesonide
|
Nasal spray, throat spray
|
+
|
+
|
+
|
|
|
|
|
|
Respiratory route
|
+
|
+
|
+
|
+
|
|
|
|
|
954
|
Budesonide + formoterol
|
Inhalation
|
+
|
+
|
+
|
|
|
|
|
|
955
|
Fenoterol + ipratropium
|
Nasal spray, throat spray, nebules
|
+
|
+
|
+
|
|
|
|
|
|
956
|
Formoterol fumarate
|
Nebules
|
+
|
+
|
+
|
|
|
|
|
|
957
|
Indacaterol
|
Inhalation
|
+
|
+
|
+
|
|
|
|
|
|
958
|
lndacaterol+ glycopyrronium
|
Inhalation
|
+
|
+
|
+
|
|
|
|
|
|
959
|
Ipratropium
|
Oral administration, Nebules
|
+
|
+
|
|
|
|
|
|
|
960
|
Sodium montelukast
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
961
|
Omalizumab
|
Injection
|
+
|
+
|
|
|
50% of the cost of drug for GINA's Step 5 treatment of persistent allergic asthma in patients aged 12 or above with positive skin test or allergen reaction (in vitro) and inadequate response to high-dose corticosteroids combined with LABA shall be covered by the Health insurance fund.
|
|
|
|
962
|
Salbutamol sulfate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, nasal spray, Respiratory route
|
+
|
+
|
+
|
+
|
|
|
|
|
963
|
Salbutamol + ipratropium
|
Nebules
|
+
|
+
|
+
|
+
|
|
|
|
|
964
|
Salmeterol + fluticasone propionate
|
Nebules, inhalation,
|
+
|
+
|
+
|
|
|
|
|
|
965
|
Terbutaline
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration, respiratory route
|
+
|
+
|
+
|
+
|
|
|
|
|
966
|
Theophylline
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
967
|
Tiotropium
|
Inhalation
|
+
|
+
|
+
|
+
|
|
|
|
|
|
25.2. Antitussives
|
|
|
|
968
|
Ambroxol
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
969
|
Bromhexine hydrochloride
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
970
|
Carbocisteine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
971
|
Carbocisteine + promethazine
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
972
|
Codeine camphosulphonate + sulfogaiacol + grindelia extract
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
973
|
Codeine + terpine hydrate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
974
|
Dextromethorphan
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
975
|
Eprazinone
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
976
|
Fenspiride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
977
|
N-acetylcysteine
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
25.3. Other drugs
|
|
|
|
978
|
Bacterial lysates of Haemophilus influenzae + Diplococcus pneumoniae + Klebsiella pneumoniae and ozaenae + Staphylococcus aureus + Streptococcus pyogenes and viridans + Neisseria catarrhalis
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
979
|
Talc powder
|
Pleural-bladder pump
|
+
|
|
|
|
|
|
|
|
980
|
Caffeine citrate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
981
|
Mometasone furoate
|
Nasal spray
|
+
|
+
|
|
|
|
|
|
|
982
|
Surfactant (Phospholipid extracted from swine or cow lung; or bovine lung surfactant)
|
Endotracheal route
|
+
|
+
|
|
|
|
|
|
|
|
26. SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES, AND OTHER SOLUTIONS FOR INFUSION
|
|
|
|
|
26.1. Oral medicines
|
|
|
|
983
|
Potassium chloride
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
984
|
Magnesium aspartate + potassium aspartate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
985
|
Sodium chloride + potassium chloride + sodium citrate + anhydrous glucose
|
Oral administration
|
+
|
+
|
+
|
+
|
Cost of drug including Sodium chloride + potassium chloride+ sodium citrate + anhydrous glucose; Sodium chloride + potassium chloride + sodium citrate + anhydrous glucose + zinc. shall be covered by the Health insurance fund.
|
|
|
|
986
|
Sodium chloride + sodium bicarbonate + potassium chloride + anhydrous dextrose
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
|
26.2. Drugs for infusion
|
|
|
|
987
|
Amino acid*
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
988
|
Amino acid + glucose + electrolyte (*)
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
989
|
Amino acid + glucose + electrolyte (*)
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
990
|
Amino acid + glucose + lipid (*)
|
Infusion
|
+
|
+
|
|
|
50% of the cost of drug including Amino acid + glucose + lipid (*); Amino acids + glucose + lipids + electrolytes (*) shall be covered by the Health insurance fund in case of patients with serious illness that cannot be fed through the gastrointestinal tract or through a tube but must be fed intravenously: resuscitation, emergency care, cancer, gastrointestinal diseases, severe malnutrition.
|
|
|
|
991
|
Calcium chloride
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
992
|
Glucose
|
Infusion
|
+
|
+
|
+
|
+
|
|
|
|
|
993
|
Potassium chloride
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
994
|
Magnesium sulfate
|
Infusion
|
+
|
+
|
+
|
+
|
|
|
|
|
995
|
Magnesium aspartate + potassium aspartate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
996
|
Manitol
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
997
|
Sodium chloride
|
Infusion
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
998
|
Sodium chloride + dextrose/glucose
|
Infusion
|
+
|
+
|
+
|
+
|
|
|
|
|
999
|
Lipid emulsion
|
Infusion
|
+
|
+
|
+
|
|
For class III and IV hospitals: Costs of drugs for treatment of anesthetic poisoning shall be covered by the Health insurance fund.
|
|
|
|
1000
|
Sodium chloride + potassium chloride + monobasic potassium phosphate + sodium acetate + Magnesium sulfate + zinc sulfate + dextrose
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
1001
|
Ringer lactate
|
Infusion
|
+
|
+
|
+
|
+
|
Cost of Ringer lactate, Ringer acetate and Ringerfundin shall be covered by the Health insurance fund.
|
|
|
|
1002
|
Sodium chloride + sodium lactate + potassium chloride + calcium chloride + glucose (Ringer lactate + glucose)
|
Infusion
|
+
|
+
|
+
|
|
|
|
|
|
|
26.3. Other drugs
|
|
|
|
1003
|
Distilled water for dilution
|
Injection
|
+
|
+
|
+
|
+
|
|
|
|
|
|
27. MINERALS AND VITAMINS
|
|
|
|
1004
|
Calcium acetate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
1005
|
Calcium carbonate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1006
|
Calcium carbonate + calcium gluconolactate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1007
|
Calcium carbonate + vitamin D3
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
1008
|
Calcium lactate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1009
|
Calcium gluconate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1010
|
Calcium glubionate
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
1011
|
Calcium glucoheptonate + vitamin D3
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
1012
|
Calcium gluconolactate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
1013
|
Calcium glycerophosphate + Magnesium gluconate
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
1014
|
Calcium-3-methyl-2-oxovalerate + calcium-4-methyl-2- oxovalerate + calcium-2-oxo-3- phenylpropionate + calcium-3- methyl-2-oxobutyrate + calcium-DL-2-hydroxy-4- methylthiobutyrate + L-lysine acetate + L-threonine + L-tryptophan + L-histidine + L- tyrosine (*)
|
Oral administration
|
+
|
|
|
|
Costs of drugs for treatment of chronic kidney failure and increased blood urea shall be covered by the Health insurance fund.
|
|
|
|
1015
|
Calcitriol
|
Oral administration
|
+
|
+
|
+
|
|
|
|
|
|
1016
|
Dibencozide
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
1017
|
Lysine + Vitamins + Minerals
|
Oral administration
|
+
|
+
|
|
|
Costs of drugs for children aged under 6 with malnutrition shall be covered by the Health insurance fund.
|
|
|
|
1018
|
Iron gluconate + manganese gluconate + copper gluconate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1019
|
Iron chloride + zinc chloride + manganese chloride + copper chloride + chromium chloride + sodium molybdate dihydrate + sodium selenide pentahydrate + sodium fluoride + potassium iodide
|
Injection
|
+
|
+
|
|
|
|
|
|
|
1020
|
Tricalcium phosphate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1021
|
Vitamin A
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1022
|
Vitamin A + D2
(Vitamin A + D3)
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1023
|
Vitamin B1
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1024
|
Vitamin B1 + B6 + B12
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
1025
|
Vitamin B2
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1026
|
Vitamin B3
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1027
|
Vitamin B5
|
Injection, oral administration
|
+
|
+
|
+
|
|
|
|
|
|
Topical administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1028
|
Vitamin B6
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1029
|
Vitamin B6 + Magnesium lactate
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1030
|
Vitamin B12 (cyanocobalamin, hydroxocobalamin)
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1031
|
Vitamin C
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1032
|
Vitamin D2
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1033
|
Vitamin D3
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
|
1034
|
Vitamin E
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
|
|
|
|
|
|
|
1035
|
Vitamin H (B8)
|
Oral administration
|
+
|
+
|
|
|
|
|
|
|
1036
|
Vitamin K
|
Injection, oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
1037
|
Vitamin PP
|
Oral administration
|
+
|
+
|
+
|
+
|
|
|
|
|
Injection
|
+
|
+
|
+
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
APPENDIX II
NOMENCLATURE OF RADIOPHARMACEUTICALS AND TRACERS UNDER HEALTH INSURANCE POLICYHOLDERS’ RECEIVED COVERAGE
(enclosed with Circular No. 20/2022/TT-BYT dated December 31, 2022 of the Minister of Health of Vietnam)
|
No
|
Name
|
Administration route
|
Form
|
Unit
|
|
(1)
|
(2)
|
(3)
|
(4)
|
(5)
|
|
1
|
BromoMercurHydrxyPropan (BMHP)
|
Intravenous injection
|
Lyophilized powder
|
vial
|
|
2
|
Carbon 11 (C-11)
|
Intravenous injection
|
Solution
|
mCi
|
|
3
|
Cesium 137 (Cesi-137)
|
Intratumoral application
|
Solid sources
|
mCi
|
|
4
|
Chromium 51 (Cr-51)
|
Intravenous injection
|
Solution
|
mCi
|
|
5
|
Cobalt 57 (Co-57)
|
Oral administration
|
Solution
|
mCi
|
|
6
|
Cobalt 60 (Co-60)
|
External radiation
|
Solid sources
|
mCi
|
|
7
|
Diethylene Triamine Pentaacetic acid (DTPA)
|
Intravenous injection, Nebules
|
Lyophilized powder
|
Vial
|
|
8
|
Dimecapto Succinic Acid (DMSA)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
9
|
Dimethyl-iminodiacetic acid (HIDA)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
10
|
Diphosphono Propane Dicarboxylic acid (DPD)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
11
|
Ethyl cysteinate dimer (ECD)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
12
|
Ethylenediamine - tetramethylenephosphonic acid (EDTMP)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
13
|
Fluorine 18 Fluoro L-DOPA (F-18DOPA)
|
Intravenous injection
|
Solution
|
mCi
|
|
14
|
Fluorine 18 Fluorodeoxyglucose (F-18FDG)
|
Intravenous injection
|
Solution
|
mCi
|
|
15
|
F18-NaF
|
Intravenous injection
|
Solution
|
mCi
|
|
16
|
Gallium citrate 67 (Ga-67)
|
Intravenous injection
|
Solution
|
mCi
|
|
17
|
Gallium citrate 68 (Ga-68)
|
Intravenous injection, arterial injection
|
Solution
|
mCi
|
|
18
|
Hexamethylpropyleamineoxime (HMPAO)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
19
|
Holmium 166 (Ho-166)
|
Tumoral injection, Tumour blood vessels
|
Solution
|
mCi
|
|
20
|
Human Albumin Microphere (HAM)
|
Intravenous injection
|
Solution
|
Vial
|
|
21
|
Human Albumin Mini-Micropheres (HAMM)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
22
|
Human Albumin Serum (HAS, SENTI-SCINT)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
23
|
Hydroxymethylene Diphosphonate (HMDP)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
24
|
Imino Diacetic Acid (IDA)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
25
|
Indiumchloride 111 (In-111)
|
Intravenous injection
|
Solution
|
mCi
|
|
26
|
Iode 123 (I-123)
|
Intravenous injection
|
Solution
|
mCi
|
|
27
|
Iode 125 (I-125)
|
Intratumoral implantation
|
Granules
|
mCi
|
|
28
|
Iode131 (I-131)
|
Oral administration
|
Tablet/Pill/Capsule/Softgel, solution
|
mCi
|
|
Intravenous injection
|
Solution
|
mCi
|
|
29
|
Iodomethyl 19 Norcholesterol
|
Intravenous injection
|
Solution
|
mCi
|
|
30
|
Iridium 192 (Ir-192)
|
External radiation
|
Solid sources
|
mCi
|
|
31
|
Au-198 Colloid
|
Intra‐articular injection
|
Solution
|
mCi
|
|
32
|
Lipiodol I-131
|
Tumoral intra-arterial injection
|
Solution
|
mCi
|
|
33
|
MacroAgregated Albumin (MAA)
|
Intravenous injection
|
Solution
|
Vial
|
|
34
|
Mecapto Acetyl Triglicerine (MAG 3)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
35
|
Metaiodbelzylguanidine (MIBG I-131)
|
Intravenous injection
|
Solution
|
mCi
|
|
36
|
Methionine
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
37
|
Methoxy isobutyl isonitrine (MIBI)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
38
|
Methylene Diphosphonate (MDP)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
39
|
Nanocis (Colloidal Rhenium Sulphide)
|
Subcutaneous injection
|
Lyophilized powder
|
Vial
|
|
40
|
Nitrogen 13- amonia
|
Intravenous injection
|
Solution
|
mCi
|
|
41
|
Octreotide Indium-111
|
Intravenous injection
|
Solution
|
mCi
|
|
42
|
Orthoiodohippurate (I-131OIH, Hippuran I-131)
|
Intravenous injection
|
Solution
|
mCi
|
|
43
|
Osteocis (Hydroxymethylene phosphonate)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
44
|
Phosphorus 32 (P-32)
|
Oral administration, intravenous injection
|
Solution
|
mCi
|
|
Transdermal administration
|
Transdermal patches
|
mCi
|
|
45
|
Phosphorus 32 (P-32) - Silicon
|
Intratumoral injection
|
Solution
|
mCi
|
|
46
|
Phytate (Phyton, Fyton)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
47
|
Pyrophosphate (Pyron)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
48
|
Rhennium 188 (Re-188)
|
Tumoral intra-arterial injection
|
Solution
|
mCi
|
|
49
|
Rose Bengal I-131
|
Intravenous injection
|
Solution
|
mCi
|
|
50
|
Samarium 153 (Sm-153)
|
Intravenous injection
|
Solution
|
mCi
|
|
51
|
Sestamibi (6-methoxy isobutyl isonitrile)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
52
|
Strontrium 89 (Sr-89)
|
Intravenous injection
|
Solution
|
mCi
|
|
53
|
Sulfur Colloid (SC)
|
Intravenous injection, subcutaneous injection
|
Lyophilized powder
|
vial
|
|
54
|
Technetium 99m (Tc-99m)
|
Intravenous injection
|
Solution
|
mCi
|
|
55
|
Teroboxime (Boronic acid adducts of technetium dioxime complexes)
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
56
|
Tetrofosmin (1,2 bis (2-ethoxyethyl) phosphino) ethane
|
Intravenous injection
|
Lyophilized powder
|
Vial
|
|
57
|
Thallium 201 (Tl-201)
|
Intravenous injection
|
Solution
|
mCi
|
|
58
|
Urea (NH2 14CoNH2)
|
Oral administration
|
Tablet/Pill/Capsule/Softgel
|
mCi
|
|
59
|
Ytrium 90 (Y-90)
|
Intra‐articular injection
|
Solution
|
mCi
|
APPENDIX III
STATISTICS OF TECHNICAL SERVICES USING RADIOACTIVE DRUGS AND TRACERS
(Applicable from .. [date]....)
(Issued together with Circular No. 20/2022/TT-BYT dated December 31, 2022 of the Minister of Health of Vietnam)
Health facility: ……………………………….
Type of technical service
TracerTracerTracerTracerTracer
Radioactive drugRadioactive drugRadioactive drugRadioactive drugRadioactive drug
|
No
|
Type of technical service
|
Tracer |
Radioactive drug |
Proposed price (VND) |
|
Name
|
Price (VND)
|
Name of tracer
|
Unit (kit/vial)
|
Unit price (VND)
|
Manufacturer's usage norm
|
Average actual usage norm
|
Sum of money (VND)
|
Name of radioactive drug
|
Unit (mci)
|
Unit price (VND)
|
Average dose
|
Average actual usage rate
|
Sum of money (VND)
|
|
|
(1)
|
(2)
|
(3)
|
(4)
|
(5)
|
(6)
|
(7)
|
(8)
|
(9)
|
(10)
|
(11)
|
(12)
|
(13)
|
(14)
|
(15)
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Prepared by
(signature and full name)
|
Department Manager ………..
(Signature and full name)
|
..[location]..,…..[date]…
Head of the health facility
(signature, full name and seal)
|
Notes:
- Col. (1): Serial number of technical service.
- Col. (2): Name of technical service using radioactive drugs and tracers.
- Col. (3): Price of technical service excluding costs of radioactive drug and tracer, approved by the competent authority.
- Col. (4) to col. (9): Criteria to calculate the cost of tracer used in the coresponding technical service, including:
+ Col. (4): Name of tracer.
+ Col. (5): Unit (kit or vial).
+ Col. (6): Unit price of tracer.
+ Col. (7): The manufacturer’s usage norm: specify usage norm prescribed by the manufacturer for the tracer of the corresponding technical service.
+ Col. (8): Average actual usage norm:
Notes: Health facility calculates the average actual usage rate of kit or vial of the tracer corresponding the technical service on the basis of the technique of the technical service and the quantity of patients directly performing the technical servce at the health facility. For example, regarding the rest myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT), in case the tracer Methoxyisobytul isonitrin (MIBI) is used and every 1 kit of MIBI can be used for 4 patients, the tracer usage norm is 1/4. The Health facility shall record this number in Col. 8 for the technical service of rest myocardial perfusion imaging (MPI) with single-photon emission computed tomography (SPECT).
- Col. (9): total amount of cost of the tracer in Col. (9) equals (=) Col. (6) multiplied by (x) Col. (8).
- Col. (10) to col. (15): Criteria to calculate the cost of radioactive drug used in the coresponding technical service, including:
+ Col. (10): name of the radioactive drug.
+ Col. (11): unit of the radioactive drug.
+ Col. (12): unit price of the radioactive drug (according to the purchase price of the health facility).
+ Col. (13): Average dose of the radioactive drug used in the coresponding technical service.
+ Col. (14): Average actual usage rate of the radioactive drug. The health facility establishes the average actual radioactive drug usage rate based on the radioactive decay rate, radioactive substance supply source, radioactive substance import cycle, and the actual number of patients using radioactive drugs at the health facility. For example, regarding I-131, based on the decay time T1/2 of 8 days, if the health facility imports it with a 15-day cycle, then on the first day the radioactive drug usage rate is 100%, but after 8 days, the radioactive drug usage rate is 50% (due to 50% decay), and after 16 days, the radioactive drug usage rate is 25% (because the remaining 50% continues to decay by half), based on the number of patients using the drug, if the health facility determines that the average actual radioactive drug usage rate of I-131 is 50%, it will be recorded in Col. (14) corresponding to 50% of I-131.
+ Col. (15): Total amount of cost of the radioactive drug in Col. (15) equals (=) Col. (12) multiplied by (x) Col. (13) divided by (:) Col. (14).
- Col. (16): Total technical service price including costs of radioactive drug and tracer, equal to (=) Col. (3) plus (+) Col. (9) plus (+) Col. (15)./.
Tìm kiếm
Thông tư 20/2022/TT-BYT (Bản Pdf)
Thông tư 20/2022/TT-BYT (Bản Word)
